

[Master's Theses](#)

[Master's Theses and Graduate Research](#)

---

2007

## Molecular detection and genotyping of human respiratory viruses

Ishmeet Kalra

*San Jose State University*

Follow this and additional works at: [https://scholarworks.sjsu.edu/etd\\_theses](https://scholarworks.sjsu.edu/etd_theses)

---

### Recommended Citation

Kalra, Ishmeet, "Molecular detection and genotyping of human respiratory viruses" (2007). *Master's Theses*. 3397.

DOI: <https://doi.org/10.31979/etd.926n-q3fj>

[https://scholarworks.sjsu.edu/etd\\_theses/3397](https://scholarworks.sjsu.edu/etd_theses/3397)

**MOLECULAR DETECTION AND GENOTYPING OF  
HUMAN RESPIRATORY VIRUSES**

A Thesis

Presented to

The Faculty of the Department of Biological Sciences

San José State University

In Partial Fulfillment

of the Requirements for the Degree

Master of Science

Concentration in Molecular Biology and Microbiology

by

Ishmeet Kalra

May 2007

## INFORMATION TO USERS

The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleed-through, substandard margins, and improper alignment can adversely affect reproduction.

In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion.



---

UMI Microform 1445242

Copyright 2007 by ProQuest Information and Learning Company.  
All rights reserved. This microform edition is protected against  
unauthorized copying under Title 17, United States Code.


ProQuest Information and Learning Company  
300 North Zeeb Road  
P.O. Box 1346  
Ann Arbor, MI 48106-1346


© 2007


Ishmeet Kalra

ALL RIGHTS RESERVED

APPROVED FOR THE DEPARTMENT OF BIOLOGICAL SCIENCES

  
Dr. John Boothby

  
Dr. Steven White

  
Dr. David Kiang, Viral and Rickettsial Disease Laboratory,  
California Department of Health Services

APPROVED FOR THE UNIVERSITY

  
Pamela C. Stark

**ABSTRACT**  
**MOLECULAR DETECTION AND GENOTYPING OF**  
**HUMAN RESPIRATORY VIRUSES**

by Ishmeet Kalra

This study describes a reverse transcription polymerase chain reaction (RT-PCR) assay targeting the 5'noncoding region (5'NCR) for genotyping human rhinoviruses (HRVs). Phylogenetic relationships among prototype strains were determined based on sequences within the 5'NCR. Sequence identity comparisons between clinical isolates and prototype strains were used to genotype clinical isolates. All HRV clinical isolates associated with a specific HRV prototype strain, except for one isolate which may represent a novel HRV. Results indicate that the 5'NCR provides a sensitive and specific target for rapidly genotyping HRVs.

Additionally, preliminary studies were performed to determine the feasibility of microarray technology for simultaneous detection and genotyping of HRVs. Microarrays containing RT-PCR products from 5'NCR and VP4/VP2 regions of various HRVs were hybridized with Cy3 - labeled cDNA from known strains. Unique and selective hybridization patterns were seen for each tested strain. Microarray technology may provide a high throughput platform for detecting and genotyping HRVs.

## ACKNOWLEDGEMENTS

I thank Dr. David Kiang for providing guidance, laboratory space, and resources for this research. I am forever indebted to Dr. John Boothby and Dr. Steven White for their time, advice, and encouragement throughout my academic career. I also thank my family and friends for their unwavering support. Lastly, but not in the least, I am grateful to my ever-patient and understanding husband, David Groch, for his unconditional love.

## TABLE OF CONTENTS

LIST OF TABLES.....	viii
LIST OF FIGURES .....	ix
PREFACE.....	1
CHAPTER I	
INTRODUCTION .....	2
CHAPTER II	
MOLECULAR DETECTION AND GENOTYPING OF HUMAN RHINOVIRUSES BASED ON THE 5' NON-CODING REGION.....	14
CHAPTER III	
USE OF MICROARRAY TECHNOLOGY FOR SIMULTANEOUS DETECTION AND GENOTYPING OF HUMAN RHINOVIRUSES .....	30
APPENDIXES .....	39
A. ADDITIONAL REFERENCES.....	40
B. WORKFLOW DIAGRAM FOR RT-PCR .....	44
C. WORKFLOW DIAGRAM FOR MICROARRAY .....	45
D. SUMMARY OF RT-PCR RESULTS.....	46
E. EXPANDED LABORATORY PROTOCOLS.....	48
F. LIST OF 5'NONCODING REGION SEQUENCES .....	53
G. LIST OF ACCESSION NUMBERS FOR SEQUENCES OBTAINED FROM GENBANK .....	85
H. EQUIPMENT USED FOR MICROARRAY .....	86

## TABLE OF CONTENTS (CONTINUED)

### APPENDIXES

I. PCR PRODUCTS SPOTTED ON MICROARRAY .....	88
J. MICROARRAY .GAL FILE .....	89
K. EXAMPLE OF MICROARRAY DATA ANALYSES.....	94

## LIST OF TABLES

Table 1. 5'NCR RT-PCR results correlating with VP4/VP2	
RT-PCR results .....	46
Table 2. 5'NCR RT-PCR results that do not correlate with VP4/VP2	
RT-PCR results .....	47
Table 3. 5'NCR RT-PCR positive isolates that were VP4/VP2 RT-PCR negative .....	47
Table 4. Concentration of PCR products spotted on microarray .....	88

## LIST OF FIGURES

Figure 1. Schematic representation of HRV genome .....	3
Figure 2. Phylogenetic clustering of HRV prototype strains based on 5'NCR sequence homology .....	28
Figure 3. Phylogenetic clustering of HRV clinical isolates with prototype strains based on 5'NCR sequence homology.....	29
Figure 4. Hybridization patterns of test cDNAs with microarrays .....	38
Figure 5. Workflow schematic of 5'NCR RT-PCR for detection and genotyping of HRV.....	44
Figure 6. Workflow schematic of microarray platform for characterizing HRV .....	45
Figure 7. Microarrayer used for spotting PCR products on aminosilane glass slides .....	86
Figure 8. Hybridization chamber with microarray .....	86
Figure 9. Scanner used for scanning microarrays after hybridization .....	87
Figure 10. Example of alignment of .gal file with the top subarray .....	94
Figure 11. Example of microarray hybridization signals sorted based on signal strength .....	95


## PREFACE

This thesis consists of three chapters and the appendixes. Each chapter is followed by a list of references cited for that particular chapter. Chapter I is a detailed introduction of the human rhinovirus, clinical manifestations of human rhinovirus infections, methods available for virus identification and typing, and the goals of the research. Chapter II and Chapter III are presented in manuscript format consistent with the Journal of Clinical Microbiology. Chapter II is a manuscript reporting the use of the reverse-transcription polymerase chain reaction assay based on the 5' non-coding region for detection and genotyping of human rhinoviruses, to be submitted for journal peer review. Chapter III is a manuscript reporting the use of microarray technology for simultaneous detection and genotyping of human rhinoviruses, also to be submitted for journal peer review. The appendixes provide additional references, as well as, additional details about the data collected and the equipment used for this research.

CHAPTER I  
INTRODUCTION

## Human Rhinovirus

Human rhinoviruses (HRV), the most frequent etiological agents of the common cold, belong to the *Picornaviridae* family (35). HRVs are non-enveloped, icosahedral, single-stranded, positive-polarity RNA viruses with a genome of approximately 7.1 kb. The genome includes a terminal VPg protein covalently attached to the 5' non-coding region (5'NCR) that is approximately 600 nucleotides (nt) long. A coding region, approximately 6500 nt long, follows the 5'NCR and includes genes which encode for viral capsid proteins and enzymes involved in polyprotein processing and genome replication. The coding region is followed by a short 3' non-coding region (3'NCR) (approximately 100 nt) and a polyA tail of about a dozen nucleotides (1) (Figure 1).



**Figure 1.** A schematic representation of HRV genome.

The HRV genome is packaged within a non-enveloped, icosahedral capsid consisting of 60 protomers arranged along a fivefold axis. Each of the protomers is composed of four viral structural proteins - VP1, VP2, VP3 which are exposed on the capsid surface, and VP4 which forms an interface between the capsid and internal genome (34). There are greater than 100 distinct serotypes of HRV that are divided into two groups based on host-cell receptor specificity. Major receptor group HRVs infect human respiratory epithelial cells using the intracellular adhesion molecule (ICAM)

receptor (25, 40). Minor receptor group HRVs utilize low density lipoprotein receptors (LDLR) to infect host cells (19). Phylogenetic studies based on the analysis of VP4/VP2 region of all prototype strains further divides human rhinoviruses into two genetic groups, HRV-A (consisting of 76 serotypes) and HRV-B (consisting of 25 serotypes) (36). Only HRV type 87 clusters individually and further characterization has revealed that it contains features of both HRV and the closely related human enterovirus (HEV) type 68, therefore, is classified as HEV-D (5). Major receptor group and minor receptor group HRVs are distributed among HRV-A and HRV-B.

### **Clinical Manifestations of Human Rhinovirus**

Human rhinoviruses have long been known to cause self-limiting, acute upper respiratory illnesses such as the “common cold” (8, 16). Common colds due to rhinovirus are usually widespread during spring and autumn (3, 14). Transmission of the virus is facilitated via direct hand-to-hand contact and aerosolization, resulting in person-to-person spread (17). Rhinorrhea, nasal stuffiness, sore throat, fever, and general malaise are characteristic symptoms of the common cold (35). On average, children experience 5 to 7 HRV infections per year, whereas adults experience 2 to 3 HRV infections per year (35). Immunity to rhinovirus is serotype-specific, therefore protection against one serotype may not prevent infections by other serotypes (15).

Although a rhinovirus cold may seem mildly inconvenient to a healthy individual, with symptoms lasting a few days, HRV infections may result in more severe symptoms in infants, elderly, and immunocompromised patients (4). HRVs have been associated with pneumonia, sinusitis, otitis media, and exacerbations of asthma and chronic

obstructive pulmonary disease in high risk populations (2, 13, 14, 18, 22, 32). Early childhood rhinovirus infections have also been linked to an increased risk of childhood asthma and allergic diseases (28). Recent HRV outbreaks in long term care facilities for elderly persons have been associated with unusually high morbidity and high mortality (18, 30, 43). Mechanisms behind these observed associations are not yet clearly understood, but there is increasing evidence that rhinoviruses may illicit cellular responses that cause injury to the respiratory epithelium (7, 9, 23).

### **Virus Identification and Subtyping**

Since acute respiratory illnesses can be caused by myriad viruses or bacteria, clinical diagnosis based solely on patient symptoms is ineffective in determining etiology. Characterization of illnesses caused by HRV is further hindered due to a lack of an animal model. Traditional laboratory diagnosis of HRV is accomplished by observing characteristic cytopathic effects (CPE) *in vitro* cell culture (12). Infection of a confluent monolayer of human fibroblasts with HRV causes CPE to appear within a week, but can take up to two weeks. CPE due to HRV infection of human fibroblasts are characterized by increase in cell granularity, rounding up of cells, cell lysis, and destruction of cell monolayer.

Neutralization assays using type-specific neutralizing antibodies from immune sera can facilitate detection, as well as, strain-typing of the virus (24). Despite being the current “gold standard”, cell culture based assays can be time-consuming and tedious due to the great number of HRV serotypes. Furthermore, intact virus particles may not be present in all collected clinical specimens, therefore, cell culture based assays requiring *in*

*vitro* replication of the virus may not be highly sensitive. Also, immune sera are in limited supply and usually restricted to research laboratories, hindering the serotyping of human rhinoviruses in routine clinical settings.

Lack of rapid, specific, and sensitive assays that can not only detect, but differentiate between rhinovirus strains, is one of the major obstacles in correlating specific rhinovirus strains with more severe symptoms. Molecular based assays are relatively inexpensive, timely, and efficient tools for characterizing HRV (20, 42). Previous molecular assays based on 3DPol, VP1, 2A, and VP4/VP2 regions have been used to characterize HRV genus phylogeny (26, 27, 36, 37). Limited evaluation of the VP4/VP2 region has been performed for genotyping of HRV clinical isolates (38). However, these regions display varying degrees of conservation and may not be able to detect variant strains or provide resolution of closely related strains of HRV.

The VP4/VP2 region is currently used at the California Department of Health Services, Viral and Rickettsial Disease Laboratory as a target for genotyping HRV clinical isolates using a reverse-transcription polymerase chain reaction (RT-PCR), as previously described (38). Although there was a high correlation between VP4/VP2 RT-PCR results and traditional microneutralization assay, a certain percentage of the clinical isolates were not detected using the molecular assay. Therefore, another candidate region that was more conserved, more specific and would possibly increase the sensitivity of the RT-PCR based assay for detecting and genotyping HRV clinical isolates was considered.

The 5'NCR was considered as a target because this region contains *cis* - elements that are involved in viral replication and translation of viral RNA and is conserved

throughout the *Picornaviridae* family. Within the 5'NCR is the internal ribosomal entry site (IRES), which is used by the virus to translate its genome in a cap-independent method. The IRES has distinct clover-leaf like structural features that is different for different picornaviruses, thus can be used to distinguish HRVs from other picornaviruses (6, 33, 46).

### **Research Goals**

The first goal of this research was to develop a reverse transcription polymerase chain reaction (RT-PCR) based molecular assay focused on approximately 400 nt region within the 5'NCR in order to detect and genotype HRVs in clinical samples. As with a previous study within the VP4/VP2 region (36), genomic sequences in the 5'NCR can be used to assess phylogenetic relationships among the prototype strains. Consequently, sequence homology comparisons between the prototype strains and clinically isolated strains can be efficiently used to genotype clinical isolates (38). This approach to genotyping can be used to collect meaningful epidemiological data that can identify circulating HRV strains involved in outbreaks and/or severe respiratory illnesses in populations at risk. Further analysis of such data should provide detailed information about specific human rhinovirus serotypes associated with more severe respiratory symptoms. Besides providing a more comprehensive understanding of the specific HRV serotypes that are involved in outbreaks, asthma exacerbations, allergies, and more severe symptoms, such data may offer insights into novel treatments and therapies for HRV infections and improve patient care via rapid diagnostics.

Secondly, we sought to develop a cDNA microarray for higher throughput detection and identification of human rhinoviruses. Microarray technology makes use of precision robotics to immobilize nucleic acids, organized as microscopic arrays, on glass slides, silicon chips, or nylon membranes (11). Further, microarrays are sensitive, require small sample volumes, and results from microarray analysis are statistically significant. Using sequence specific hybridization of nucleic acids, microarrays can be used to study genomics, targets for drug discovery, candidates for vaccine development, and evolution (10, 21, 39, 45). Such technology can also be used in novel ways to detect as well as subtype viruses (29, 31, 41, 44). Microarray based diagnostics can eliminate the need for PCR amplification and sequencing for genotyping clinical isolates, leading to rapid, sensitive, and specific viral diagnostics.

The proposed cDNA microarray will be spotted with purified RT-PCR products, from the 5'NCR and the VP4/VP2 regions of HRV prototype as well as HRV clinical isolates, on aminosilane coated glass slides. Microarrays will then be hybridized with fluorescently labeled test cDNA to detect and subtype human rhinoviruses based on unique hybridization patterns and signal strength. In the future, the cDNA microarray platform can be further expanded to include additional respiratory viruses, such as influenza and enteroviruses, to create a respiratory diagnostic panel.

## REFERENCES CITED

1. **Agol, V. I.** 2002. Picornavirus Genome: an Overview. In B. L. a. E. W. Semler (ed.), Molecular biology of Picornaviruses. ASM Press, Washington, D.C.
2. **Arola, M., O. Ruuskanen, T. Ziegler, J. Mertsola, K. Nanto-Salonen, A. Putto-Laurila, M. K. Viljanen, and P. Halonen.** 1990. Clinical role of respiratory virus infection in acute otitis media. *Pediatrics* **86**:848-55.
3. **Arruda, E., A. Pitkaranta, T. J. Witek, Jr., C. A. Doyle, and F. G. Hayden.** 1997. Frequency and natural history of rhinovirus infections in adults during autumn. *J Clin Microbiol* **35**:2864-8.
4. **Atmar, R. L.** 2005. Uncommon(ly considered) manifestations of infection with rhinovirus, agent of the common cold. *Clin Infect Dis* **41**:266-7.
5. **Blomqvist, S., C. Savolainen, L. Raman, M. Roivainen, and T. Hovi.** 2002. Human rhinovirus 87 and enterovirus 68 represent a unique serotype with rhinovirus and enterovirus features. *J Clin Microbiol* **40**:4218-23.
6. **Borman, A. M., J. L. Bailly, M. Girard, and K. M. Kean.** 1995. Picornavirus internal ribosome entry segments: comparison of translation efficiency and the requirements for optimal internal initiation of translation in vitro. *Nucleic Acids Res* **23**:3656-63.
7. **Bossios, A., S. Psarras, D. Gourgiotis, C. L. Skevaki, A. G. Constantopoulos, P. Saxoni-Papageorgiou, and N. G. Papadopoulos.** 2005. Rhinovirus infection induces cytotoxicity and delays wound healing in bronchial epithelial cells. *Respir Res* **6**:114.
8. **Cate, T. R., R. B. Couch, and K. M. Johnson.** 1964. Studies With Rhinoviruses In Volunteers: Production Of Illness, Effect Of Naturally Acquired Antibody, And Demonstration Of A Protective Effect Not Associated With Serum Antibody. *J Clin Invest* **43**:56-67.
9. **Deszcz, L., E. Gaudernak, E. Kuechler, and J. Seipelt.** 2005. Apoptotic events induced by human rhinovirus infection. *J Gen Virol* **86**:1379-89.
10. **Dhiman, N., R. Bonilla, D. J. O'Kane, and G. A. Poland.** 2001. Gene expression microarrays: a 21st century tool for directed vaccine design. *Vaccine* **20**:22-30.
11. **Epstein, C. B., and R. A. Butow.** 2000. Microarray technology - enhanced versatility, persistent challenge. *Curr Opin Biotechnol* **11**:36-41.

12. **Fiala, M.** 1968. Plaque formation by 55 rhinovirus serotypes. *Appl Microbiol* **16**:1445-50.
13. **Friedlander, S. L., and W. W. Busse.** 2005. The role of rhinovirus in asthma exacerbations. *J Allergy Clin Immunol* **116**:267-73.
14. **Gern, J. E., and W. W. Busse.** 1999. Association of rhinovirus infections with asthma. *Clin Microbiol Rev* **12**:9-18.
15. **Gwaltney, J. M., Jr.** 1985. Virology and immunology of the common cold. *Rhinology* **23**:265-71.
16. **Gwaltney, J. M., Jr., and W. S. Jordan, Jr.** 1964. Rhinoviruses And Respiratory Disease. *Bacteriol Rev* **28**:409-22.
17. **Gwaltney, J. M., Jr., P. B. Moskalski, and J. O. Hendley.** 1978. Hand-to-hand transmission of rhinovirus colds. *Ann Intern Med* **88**:463-7.
18. **Hicks, L. A., C. W. Shepard, P. H. Britz, D. D. Erdman, M. Fischer, B. L. Flannery, A. J. Peck, X. Lu, W. L. Thacker, R. F. Benson, M. L. Tondella, M. E. Moll, C. G. Whitney, L. J. Anderson, and D. R. Feikin.** 2006. Two outbreaks of severe respiratory disease in nursing homes associated with rhinovirus. *J Am Geriatr Soc* **54**:284-9.
19. **Hofer, F., M. Gruenberger, H. Kowalski, H. Machat, M. Huettlinger, E. Kuechler, and D. Blaas.** 1994. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. *Proc Natl Acad Sci U S A* **91**:1839-42.
20. **Hyypia, T., T. Puhakka, O. Ruuskanen, M. Makela, A. Arola, and P. Arstila.** 1998. Molecular diagnosis of human rhinovirus infections: comparison with virus isolation. *J Clin Microbiol* **36**:2081-3.
21. **Izuhara, K., and H. Saito.** 2006. Microarray-based identification of novel biomarkers in asthma. *Allergol Int* **55**:361-7.
22. **Johnston, S. L., P. G. Bardin, and P. K. Pattemore.** 1993. Viruses as precipitants of asthma symptoms. III. Rhinoviruses: molecular biology and prospects for future intervention. *Clin Exp Allergy* **23**:237-46.
23. **Konno, S., K. A. Grindle, W. M. Lee, M. K. Schroth, A. G. Mosser, R. A. Brockman-Schneider, W. W. Busse, and J. E. Gern.** 2002. Interferon-gamma enhances rhinovirus-induced RANTES secretion by airway epithelial cells. *Am J Respir Cell Mol Biol* **26**:594-601.

24. **Kriel, R. L., H. Wulff, and T. D. Chin.** 1969. Microneutralization test for determination of rhinovirus and coxsackievirus A antibody in human diploid cells. *Appl Microbiol* **17**:611-3.
25. **Kuhn, R. J., and M. G. Rossmann.** 2002. Interaction of Major Group Rhinoviruses with Their Cellular Receptor, ICAM-1. In B. L. a. E. W. Semler (ed.), *Molecular biology of Picornaviruses*. ASM Press, Washington, D.C.
26. **Laine, P., C. Savolainen, S. Blomqvist, and T. Hovi.** 2005. Phylogenetic analysis of human rhinovirus capsid protein VP1 and 2A protease coding sequences confirms shared genus-like relationships with human enteroviruses. *J Gen Virol* **86**:697-706.
27. **Ledford, R. M., N. R. Patel, T. M. Demenczuk, A. Watanyar, T. Herbertz, M. S. Collett, and D. C. Pevear.** 2004. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. *J Virol* **78**:3663-74.
28. **Lemanske, R. F., Jr., D. J. Jackson, R. E. Gangnon, M. D. Evans, Z. Li, P. A. Shult, C. J. Kirk, E. Reisdorf, K. A. Roberg, E. L. Anderson, K. T. Carlson-Dakes, K. J. Adler, S. Gilbertson-White, T. E. Pappas, D. F. Dasilva, C. J. Tisler, and J. E. Gern.** 2005. Rhinovirus illnesses during infancy predict subsequent childhood wheezing. *J Allergy Clin Immunol* **116**:571-7.
29. **Lodes, M. J., D. Suciu, M. Elliott, A. G. Stover, M. Ross, M. Caraballo, K. Dix, J. Crye, R. J. Webby, W. J. Lyon, D. L. Danley, and A. McShea.** 2006. Use of semiconductor-based oligonucleotide microarrays for influenza a virus subtype identification and sequencing. *J Clin Microbiol* **44**:1209-18.
30. **Louie, J. K., S. Yagi, F. A. Nelson, D. Kiang, C. A. Glaser, J. Rosenberg, C. K. Cahill, and D. P. Schnurr.** 2005. Rhinovirus outbreak in a long term care facility for elderly persons associated with unusually high mortality. *Clin Infect Dis* **41**:262-5.
31. **Nordstrom, H., K. I. Falk, G. Lindgren, M. Mouzavi-Jazi, A. Walden, F. Elgh, P. Nilsson, and A. Lundkvist.** 2005. DNA microarray technique for detection and identification of seven flaviviruses pathogenic for man. *J Med Virol* **77**:528-40.
32. **Pitkaranta, A., E. Arruda, H. Malmberg, and F. G. Hayden.** 1997. Detection of rhinovirus in sinus brushings of patients with acute community-acquired sinusitis by reverse transcription-PCR. *J Clin Microbiol* **35**:1791-3.

33. **Rivera, V. M., J. D. Welsh, and J. V. Maizel, Jr.** 1988. Comparative sequence analysis of the 5' noncoding region of the enteroviruses and rhinoviruses. *Virology* **165**:42-50.
34. **Rossmann, M. G.** 2002. Picornavirus Structure Overview. In B. L. a. E. W. Semler (ed.), *Molecular biology of Picornaviruses*. ASM Press, Washington, D.C.
35. **Rotbart, H. A.** 2002. Clinical Significance, Diagnosis, and Treatment of Picornavirus Infections. In B. L. a. E. W. Semler (ed.), *Molecular biology of Picornaviruses*. ASM Press, Washington, D.C.
36. **Savolainen, C., S. Blomqvist, M. N. Mulders, and T. Hovi.** 2002. Genetic clustering of all 102 human rhinovirus prototype strains: serotype 87 is close to human enterovirus 70. *J Gen Virol* **83**:333-40.
37. **Savolainen, C., P. Laine, M. N. Mulders, and T. Hovi.** 2004. Sequence analysis of human rhinoviruses in the RNA-dependent RNA polymerase coding region reveals large within-species variation. *J Gen Virol* **85**:2271-7.
38. **Savolainen, C., M. N. Mulders, and T. Hovi.** 2002. Phylogenetic analysis of rhinovirus isolates collected during successive epidemic seasons. *Virus Res* **85**:41-6.
39. **Schneider, R. A.** 2007. How to tweak a beak: molecular techniques for studying the evolution of size and shape in Darwin's finches and other birds. *Bioessays* **29**:1-6.
40. **Tomassini, J. E., D. Graham, C. M. DeWitt, D. W. Lineberger, J. A. Rodkey, and R. J. Colonna.** 1989. cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1. *Proc Natl Acad Sci U S A* **86**:4907-11.
41. **Townsend, M. B., E. D. Dawson, M. Mehlmann, J. A. Smagala, D. M. Dankbar, C. L. Moore, C. B. Smith, N. J. Cox, R. D. Kuchta, and K. L. Rowlen.** 2006. Experimental evaluation of the FluChip diagnostic microarray for influenza virus surveillance. *J Clin Microbiol* **44**:2863-71.
42. **Vuorinen, T., R. Vainionpaa, and T. Hyypia.** 2003. Five years' experience of reverse-transcriptase polymerase chain reaction in daily diagnosis of enterovirus and rhinovirus infections. *Clin Infect Dis* **37**:452-5.
43. **Wald, T. G., P. Shult, P. Krause, B. A. Miller, P. Drinka, and S. Gravenstein.** 1995. A rhinovirus outbreak among residents of a long-term care facility. *Ann Intern Med* **123**:588-93.

44. **Wang, D., L. Coscoy, M. Zylberberg, P. C. Avila, H. A. Boushey, D. Ganem, and J. L. DeRisi.** 2002. Microarray-based detection and genotyping of viral pathogens. *Proc Natl Acad Sci U S A* **99**:15687-92.
45. **Yao, P. L., M. F. Tsai, Y. C. Lin, C. H. Wang, W. Y. Liao, J. J. Chen, and P. C. Yang.** 2005. Global expression profiling of theophylline response genes in macrophages: evidence of airway anti-inflammatory regulation. *Respir Res* **6**:89.
46. **Zell, R., and A. Stelzner.** 1997. Application of genome sequence information to the classification of bovine enteroviruses: the importance of 5'- and 3'-nontranslated regions. *Virus Res* **51**:213-29.

## CHAPTER II

### MOLECULAR DETECTION AND GENOTYPING OF HUMAN RHINOVIRUSES BASED ON THE 5' NON-CODING REGION

MOLECULAR DETECTION AND GENOTYPING OF HUMAN RHINOVIRUSES  
BASED ON THE 5' NON-CODING REGION

*I. Kalra*<sup>1,2</sup>, *D. Kiang*<sup>1,2,\*</sup>, *S. Yagi*<sup>1</sup>, *J. Boothby*<sup>2</sup>, *D. Schnurr*<sup>1</sup>

<sup>1</sup> *Viral and Rickettsial Disease Laboratory,  
California Department of Health Services,  
Richmond, CA 94804*

<sup>2</sup> *Department of Biological Sciences,  
San José State University,  
San José, CA 95192*

\* Corresponding author. Mailing address: Viral and Rickettsial Disease Laboratory, California Department of Health Services, 850 Marina Bay Parkway, Richmond, CA 94804. Phone: (510) 307-8618. Fax: (510) 307-8699. Email: dkiang@dhs.ca.gov

## **Abstract**

Human rhinoviruses (HRV), belonging to the *Picornaviridae* family, are the most frequent etiological agents of the common cold. Additionally, human rhinoviruses have been associated with more severe respiratory exacerbations in young children, elderly, and immunocompromised patients. HRVs are non-enveloped, icosahedral, single-stranded, positive-polarity RNA viruses with a genome of approximately 7.1 kb that includes a 5'noncoding region (5'NCR). The 5'NCR contains *cis* - elements that are involved in viral replication and translation of viral RNA, and is fairly conserved for picornaviruses. Since, there are greater than 100 distinct serotypes of HRVs, traditional serotyping to type HRVs is tedious, time-consuming, and inefficient. Molecular based genotyping assays provide an effective alternative to identify and differentiate between HRV strains. Molecular genotyping can be used to correlate specific strains to specific illnesses, provide meaningful epidemiological data, and help identify targets for future therapies.

We have developed a reverse transcription polymerase chain reaction (RT-PCR) based assay targeting the 5'NCR to genotype HRVs in clinical samples. Genomic sequences within 5' NCR were determined for all human rhinovirus prototype strains and used to assess their phylogenetic relationships. Sequence identity comparisons of clinical isolates with prototype strains were used to genotype clinical isolates. Using this approach, all clinical isolates associated with a single HRV prototype strain, with the exception of one isolate that may potentially be a novel HRV strain. Our results suggest

that the 5'NCR is a sensitive, specific target for rapid and cost effective means to genotype HRVs in clinical samples.

## **Introduction**

Human rhinovirus (HRV), belonging to the *Picornaviridae* family, are responsible for causing a majority of the common colds with symptoms of rhinitis, fever, sore throat, and general malaise (8, 25). HRVs are non-enveloped, icosahedral, positive-polarity RNA viruses which have a single stranded genome of approximately 7.1 kb that includes a terminal VPg protein, a 5' non-coding region (5'NCR), genes encoding structural and non-structural proteins, followed by a 3' non-coding region (3'NCR), and a polyA tail (24). There are greater than 100 distinct serotypes of HRV that are divided into two groups based on host-cell receptor specificity. Major receptor group HRVs infect human respiratory epithelial cells using the intracellular adhesion molecule (ICAM) receptor (15, 30). Minor receptor group HRVs utilize low density lipoprotein receptors (LDLR) to infect host cells (12). Phylogenetic studies based on the analysis of VP4/VP2 region of all prototype strains further divide human rhinoviruses into two groups, HRV-A (consisting of 76 serotypes) and HRV-B (consisting of 25 serotypes) (27). Only HRV type 87 clusters individually and further characterization has revealed that it contains features of both HRV and the closely related human enterovirus (HEV) type 68, therefore, is classified as HEV-D (6).

Although most rhinovirus infections are self-limiting acute upper respiratory tract infections, recent studies suggest that HRVs can replicate in the lower respiratory tract and cause more severe disease in infants, elderly, and immunocompromised patients (2,

4, 9). HRVs have been associated with pneumonia, sinusitis, otitis media, and exacerbations of asthma and chronic obstructive pulmonary disease in high risk populations (3, 10, 11, 18, 22, 23). Early childhood rhinovirus infections have been linked to an increased risk of childhood asthma and allergic diseases (19). Recent HRV outbreaks in long term care facilities for the elderly persons have been associated with unusually high morbidity and high mortality (11, 20, 32).

Traditional laboratory diagnosis to identify HRV in clinical specimens is based on protection of cells *in vitro* by virus - neutralizing antibodies (14). Cell culture based assays are relatively costly, time-consuming, tedious, and impractical due to the great number of HRV serotypes and limited supply of immune sera (26). Alternatively, molecular based assays present cost effective, timely, and efficient tools for characterizing HRV (1, 5, 13, 21, 31). Previous molecular assays based on 3DPol, VP1, 2A, VP4/VP2 regions have been used to characterize HRV genus phylogeny (16, 17, 27, 28). Limited evaluation of the VP4/VP2 region has been performed for genotyping of HRV clinical isolates (29). However, the variability in conservation of these regions across the HRV genus can decrease specificity and the sensitivity of molecular diagnostics.

The 5'NCR was considered as a candidate region for reverse transcription polymerase chain reaction (RT-PCR) based genotyping of HRV in clinical samples. This region contains *cis* - elements involved in viral replication and translation of viral RNA and is fairly conserved within the *Picornaviridae* family (7). The 5'NCR contains an internal ribosomal entry site (IRES) that is used by the virus to translate its genome in a

cap-independent method. The IRES has distinct clover-leaf like structural features that can be used to distinguish HRVs from the closely related HEVs (33). As with a previous study within the VP4/VP2 region (27), genomic sequences in the 5'NCR can be used to assess phylogenetic relationships among the prototype strains. Consequently, sequence homology comparisons between the prototype strains and clinically isolated strains can be efficiently used to genotype clinical isolates (29). The purpose of this study is to use phylogenetic analyses of sequence comparisons within the 5'NCR to characterize and subtype HRV clinical isolates.

### **Materials and Methods**

**Virus strains.** Seventy - six prototype HRV strains and 97 clinical HRV isolate strains were provided by the Viral and Rickettsial Disease Laboratory at the California Department of Health Services (Richmond, CA).

**Media and growth conditions.** To ensure good working titers, virus was expanded by infecting a confluent monolayer of human fetal diploid lung cells (maintained in 98% MEM Eagle with Hanks, 2% FCS) at 33°C until full cytopathic effects were observed (for up to 2 weeks). Cultures were frozen at -80°C and thawed at room temperature three times and centrifuged at 2000 Gs for 15 minutes at room temperature to release virus and remove cell debris. The cell culture supernatant containing virus (in same media) was aliquoted in 1 ml quantities and stored at -80°C.

**Viral total RNA extraction.** Total viral RNA was extracted from 150  $\mu$ l of cell culture supernatant using QIAamp Viral RNA Mini Spin Kit (Qiagen, Valencia, CA) as per manufacturer instructions.

**Reverse transcription polymerase chain reaction.** First strand cDNA was synthesized using 5  $\mu$ l of extracted viral RNA, random hexamer primers and SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA), as per manufacturer instructions. Primers for PCR amplification of a fragment within the 5'NCR were designed based on an alignment of available HRV 5'NCR sequences within the GenBank database (NCBI). Forward primer RV179F 5'-CAAGCACTTCTGTTCCC-3' and reverse primer RV568R 5'-CACGGACACCCAAAGTAGT-3', were used to PCR amplify a region within the 5'NCR using 2  $\mu$ l of cDNA template 2.5 U of PfuTurbo DNA polymerase (Stratagene, Cedar Creek, TX), 0.8 U of Taq DNA polymerase (Invitrogen, Carlsbad, CA), and 1  $\mu$ l of 100mM dNTP set (Invitrogen, Carlsbad, CA) in a final reaction volume of 50  $\mu$ l. PCR conditions were as follows: hot start at 95°C (5 min) followed by forty cycles of denaturation at 95°C (15 s), annealing at 55°C (15 s), and elongation at 72°C (60 s) resulting in amplification of fragments approximately 350-400 nt in length.

**Gel electrophoresis.** Five microliters of each RT-PCR product was mixed with 1  $\mu$ l of 6X loading buffer and subjected to 1% agarose gel electrophoresis. The gels were visualized after staining with ethidium bromide.

**Purification and sequencing of PCR products.** PCR products were purified using QIAquick PCR Purification Kit (Qiagen, Valencia, CA) and sequenced in both directions using Sanger dideoxy cycle sequencing method with the ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA) as per manufacturer instructions. Published HRV sequences within the 5'NCR were obtained from GenBank database (NCBI).

**Sequence alignment and phylogenetic analyses.** Sequences were aligned using ClustalX (v1.83). Multiple sequence alignment was subjected to phylogenetic analyses using programs in the PHYLIP package (v3.6). Distance matrices were calculated using DNAdist. Data was bootstrapped using SEQBOOT, and phylogenetic relationships were assessed using neighbor-joining, maximum parsimony, and maximum likelihood methods. Consensus trees were computed using CONSENSE and phylogenetic trees were visualized using TREEVIEW (v1.6.6).

## Results

All HRV prototype strains had unique genomic sequences in the 5'NCR and clustered into two groups, HRV-A and HRV-B (Figure 2). Further, sequence identity comparisons between the prototype strains and clinically isolated strains led to association of clinical isolates with a single prototype strain of HRV, with the exception of one isolate, BMT-303 (Figure 3). In total, 82 clinical isolates were 5'NCR RT-PCR positive, whereas, previously, only 79 clinical isolates were VP4/VP2 RT-PCR positive. Comparison with the VP4/VP2 RT-PCR and the 5'NCR RT-PCR indicate that 5'NCR RT-PCR was able to detect a higher percentage of HRV (84.54%) than VP4/VP2 RT-PCR (72.1%) in clinical specimens. There was a high correlation (98.57%) of 5'NCR results with previous VP4/VP2 results. A single isolate, V06T01482, differed with respect to VP4/VP2 and 5'NCR RT-PCR results. Also, in certain cases, we found that the 5'NCR RT-PCR could effectively detect and differentiate between HRV and HEV.

## **Discussion**

Our results indicate that RT-PCR targeting the 5'NCR can be efficiently used to infer phylogenetic relationships between HRV prototype strains. Based on the 5'NCR, all HRV prototype strains clustered into two groups, HRV-A and HRV-B, as previously reported with VP4/VP2 analysis (27). Sequence homology between HRV prototype strains and HRV clinical isolates can be effectively used to genotype HRV clinical isolates. Except for a single isolate, BMT-303, all clinical isolates clustered with a single prototype strain. BMT-303, isolated from a bone marrow transplant recipient, may represent a novel strain of human rhinovirus based on sequence divergence. We are in the process of further characterizing this isolate.

The high correlation between previously evaluated VP4/VP2 RT-PCR and 5'NCR RT-PCR implies that sequences within the 5'NCR are strain specific and can be used to subtype HRVs. A single discrepancy, V06T01482, may have occurred because of multiple HRV strains in the clinical sample as result of a coinfection. Additionally, we found that 5'NCR RT-PCR was more sensitive and specific than the VP4/VP2 RT-PCR, allowing detection and genotyping of 12 additional isolate strains. In a few cases, the 5'NCR could effectively differentiate between HRV and the closely related genera, HEV.

Although, additional studies correlating molecular genotyping results with traditional neutralization assays are needed, a molecular approach for genotyping HRV clinical isolates can facilitate collection and analysis of epidemiological data. Future studies that can reliably genotype clinical isolates may allow correlation of specific HRV

strains with more severe symptoms, as well as, allow for the discovery and characterization of novel strains.

### **Acknowledgments**

This work is supported by the California Department of Health Services and a National Institutes of Allergy and Infectious Diseases Grant AI-50496 (PPG).


## REFERENCES CITED

1. **Andeweg, A. C., T. M. Bestebroer, M. Huybreghs, T. G. Kimman, and J. C. de Jong.** 1999. Improved detection of rhinoviruses in clinical samples by using a newly developed nested reverse transcription-PCR assay. *J Clin Microbiol* **37**:524-30.
2. **Arden, K. E., P. McErlean, M. D. Nissen, T. P. Sloots, and I. M. Mackay.** 2006. Frequent detection of human rhinoviruses, paramyxoviruses, coronaviruses, and bocavirus during acute respiratory tract infections. *J Med Virol* **78**:1232-40.
3. **Arola, M., O. Ruuskanen, T. Ziegler, J. Mertsola, K. Nanto-Salonen, A. Putto-Laurila, M. K. Viljanen, and P. Halonen.** 1990. Clinical role of respiratory virus infection in acute otitis media. *Pediatrics* **86**:848-55.
4. **Atmar, R. L.** 2005. Uncommon(ly considered) manifestations of infection with rhinovirus, agent of the common cold. *Clin Infect Dis* **41**:266-7.
5. **Atmar, R. L., and P. R. Georghiou.** 1993. Classification of respiratory tract picornavirus isolates as enteroviruses or rhinoviruses by using reverse transcription-polymerase chain reaction. *J Clin Microbiol* **31**:2544-6.
6. **Blomqvist, S., C. Savolainen, L. Raman, M. Roivainen, and T. Hovi.** 2002. Human rhinovirus 87 and enterovirus 68 represent a unique serotype with rhinovirus and enterovirus features. *J Clin Microbiol* **40**:4218-23.
7. **Borman, A. M., J. L. Bailly, M. Girard, and K. M. Kean.** 1995. Picornavirus internal ribosome entry segments: comparison of translation efficiency and the requirements for optimal internal initiation of translation in vitro. *Nucleic Acids Res* **23**:3656-63.
8. **Cate, T. R., R. B. Couch, and K. M. Johnson.** 1964. Studies With Rhinoviruses In Volunteers: Production Of Illness, Effect Of Naturally Acquired Antibody, And Demonstration Of A Protective Effect Not Associated With Serum Antibody. *J Clin Invest* **43**:56-67.
9. **Friedlander, S. L., and W. W. Busse.** 2005. The role of rhinovirus in asthma exacerbations. *J Allergy Clin Immunol* **116**:267-73.
10. **Gern, J. E., and W. W. Busse.** 1999. Association of rhinovirus infections with asthma. *Clin Microbiol Rev* **12**:9-18.


11. **Hicks, L. A., C. W. Shepard, P. H. Britz, D. D. Erdman, M. Fischer, B. L. Flannery, A. J. Peck, X. Lu, W. L. Thacker, R. F. Benson, M. L. Tondella, M. E. Moll, C. G. Whitney, L. J. Anderson, and D. R. Feikin.** 2006. Two outbreaks of severe respiratory disease in nursing homes associated with rhinovirus. *J Am Geriatr Soc* **54**:284-9.
12. **Hofer, F., M. Gruenberger, H. Kowalski, H. Machat, M. Huettinger, E. Kuechler, and D. Blaas.** 1994. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. *Proc Natl Acad Sci U S A* **91**:1839-42.
13. **Hyypia, T., T. Puhakka, O. Ruuskanen, M. Makela, A. Arola, and P. Arstila.** 1998. Molecular diagnosis of human rhinovirus infections: comparison with virus isolation. *J Clin Microbiol* **36**:2081-3.
14. **Kriell, R. L., H. Wulff, and T. D. Chin.** 1969. Microneutralization test for determination of rhinovirus and coxsackievirus A antibody in human diploid cells. *Appl Microbiol* **17**:611-3.
15. **Kuhn, R. J., and M. G. Rossmann.** 2002. Interaction of Major Group Rhinoviruses with Their Cellular Receptor, ICAM-1. In B. L. a. E. W. Semler (ed.), *Molecular biology of Picornaviruses*. ASM Press, Washington, D.C.
16. **Laine, P., C. Savolainen, S. Blomqvist, and T. Hovi.** 2005. Phylogenetic analysis of human rhinovirus capsid protein VP1 and 2A protease coding sequences confirms shared genus-like relationships with human enteroviruses. *J Gen Virol* **86**:697-706.
17. **Ledford, R. M., N. R. Patel, T. M. Demenczuk, A. Watanyar, T. Herbertz, M. S. Collett, and D. C. Pevear.** 2004. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. *J Virol* **78**:3663-74.
18. **Lemanske, R. F., Jr., E. C. Dick, C. A. Swenson, R. F. Vrtis, and W. W. Busse.** 1989. Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. *J Clin Invest* **83**:1-10.
19. **Lemanske, R. F., Jr., D. J. Jackson, R. E. Gangnon, M. D. Evans, Z. Li, P. A. Shult, C. J. Kirk, E. Reisdorf, K. A. Roberg, E. L. Anderson, K. T. Carlson-Dakes, K. J. Adler, S. Gilbertson-White, T. E. Pappas, D. F. Dasilva, C. J. Tisler, and J. E. Gern.** 2005. Rhinovirus illnesses during infancy predict subsequent childhood wheezing. *J Allergy Clin Immunol* **116**:571-7.

20. **Louie, J. K., S. Yagi, F. A. Nelson, D. Kiang, C. A. Glaser, J. Rosenberg, C. K. Cahill, and D. P. Schnurr.** 2005. Rhinovirus outbreak in a long term care facility for elderly persons associated with unusually high mortality. *Clin Infect Dis* **41**:262-5.
21. **Mori, J., and J. P. Clewley.** 1994. Polymerase chain reaction and sequencing for typing rhinovirus RNA. *J Med Virol* **44**:323-9.
22. **Papadopoulos, N., and S. Johnston.** 2001. The rhinovirus--not such an innocent? *Qjm* **94**:1-3.
23. **Pitkaranta, A., E. Arruda, H. Malmberg, and F. G. Hayden.** 1997. Detection of rhinovirus in sinus brushings of patients with acute community-acquired sinusitis by reverse transcription-PCR. *J Clin Microbiol* **35**:1791-3.
24. **Rossmann, M. G.** 2002. Picornavirus Structure Overview. In B. L. a. E. W. Semler (ed.), Molecular biology of Picornaviruses. ASM Press, Washington, D.C.
25. **Rotbart, H. A.** 2002. Clinical Significance, Diagnosis, and Treatment of Picornavirus Infections. In B. L. a. E. W. Semler (ed.), Molecular biology of Picornaviruses. ASM Press, Washington, D.C.
26. **Savolainen, C., S. Blomqvist, and T. Hovi.** 2003. Human rhinoviruses. *Paediatr Respir Rev* **4**:91-8.
27. **Savolainen, C., S. Blomqvist, M. N. Mulders, and T. Hovi.** 2002. Genetic clustering of all 102 human rhinovirus prototype strains: serotype 87 is close to human enterovirus 70. *J Gen Virol* **83**:333-40.
28. **Savolainen, C., P. Laine, M. N. Mulders, and T. Hovi.** 2004. Sequence analysis of human rhinoviruses in the RNA-dependent RNA polymerase coding region reveals large within-species variation. *J Gen Virol* **85**:2271-7.
29. **Savolainen, C., M. N. Mulders, and T. Hovi.** 2002. Phylogenetic analysis of rhinovirus isolates collected during successive epidemic seasons. *Virus Res* **85**:41-6.
30. **Tomassini, J. E., D. Graham, C. M. DeWitt, D. W. Lineberger, J. A. Rodkey, and R. J. Colonna.** 1989. cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1. *Proc Natl Acad Sci U S A* **86**:4907-11.

31. **Vuorinen, T., R. Vainionpaa, and T. Hyypia.** 2003. Five years' experience of reverse-transcriptase polymerase chain reaction in daily diagnosis of enterovirus and rhinovirus infections. *Clin Infect Dis* **37**:452-5.
32. **Wald, T. G., P. Shult, P. Krause, B. A. Miller, P. Drinka, and S. Gravenstein.** 1995. A rhinovirus outbreak among residents of a long-term care facility. *Ann Intern Med* **123**:588-93.
33. **Zell, R., and A. Stelzner.** 1997. Application of genome sequence information to the classification of bovine enteroviruses: the importance of 5'- and 3'-nontranslated regions. *Virus Res* **51**:213-29.



**Figure 2.** Phylogenetic clustering of HRV prototype strains based on the 5'NCR. Prototype strains cluster into Group A and B as expected.



**Figure 3.** Phylogenetic clustering of clinical isolates with HRV prototype strains based on 5'NCR sequence homology. Prototype strains are highlighted in purple and clinical isolates in red.

### **CHAPTER III**

#### **USE OF MICROARRAY TECHNOLOGY FOR SIMULTANEOUS DETECTION AND GENOTYPING OF HUMAN RHINOVIRUSES**

USE OF MICROARRAY TECHNOLOGY FOR SIMULTANEOUS DETECTION  
AND GENOTYPING OF HUMAN RHINOVIRUSES

*I. Kalra<sup>1,2</sup>, D. Kiang<sup>1,2,\*</sup>, E. Chou<sup>1</sup>, S. Yagi<sup>1</sup>, J. Boothby<sup>2</sup>, D. Schnurr<sup>1</sup>*

*<sup>1</sup> Viral and Rickettsial Disease Laboratory,  
California Department of Health Services,  
Richmond, CA 94804*

*<sup>2</sup> Department of Biological Sciences,  
San José State University,  
San José, CA 95192*

\* Corresponding author. Mailing address: Viral and Rickettsial Disease Laboratory, California Department of Health Services, 850 Marina Bay Parkway, Richmond, CA 94804. Phone: (510) 307-8618. Fax: (510) 307-8699. Email: dkiang@dhs.ca.gov

## **Abstract**

Use of microarray technology to simultaneously detect and genotype human rhinoviruses (HRVs) based on the 5' non-coding region (5'NCR) and VP4/VP2 region was evaluated. Microarrays, containing RT-PCR products from 5'NCR and VP4/VP2 regions of various prototypes and clinically isolated HRV strains, were constructed. Each sample was represented in triplicate on two subarrays and tested against labeled cDNA from known prototype strains and previously genotyped clinical isolates. Unique and selective hybridization patterns were seen for each tested strain. Preliminary results indicate that microarrays have the potential to provide a highly efficient and high throughput platform for simultaneous detection and genotyping of HRVs.

## **Introduction**

Microarray technology uses precision robotics to produce microscopic arrays of immobilized nucleic acids on glass slides, silicone chips, or nylon membranes (2). Such technology takes advantage of sequence specific hybridization of nucleic acids and is applicable to fields of genomics, drug discovery, vaccine design, and evolution (1, 3, 6, 10). Microarrays have revolutionized viral diagnostics by allowing rapid testing of clinical specimens to identify and subtype viral pathogens (4, 5, 7-9). This approach can provide a highly efficient, sensitive and specific platform for simultaneous screening of multiple pathogens in the routine clinical setting.

Due to the great number of serotypes of HRVs, traditional laboratory diagnostics to characterize HRVs in clinical samples can be tedious, time-consuming, and inefficient. Microarrays offer an attractive alternative to effectively detect and type HRVs because

such technology can greatly reduce workload in a laboratory setting. Possibility of high capacity and high throughput analysis can also lead to collection of meaningful epidemiological data correlating specific HRV strains with more severe illnesses or epidemics. Microarrays can also be used to detect novel strains of virus based on hybridization of conserved sequences. This study describes the development of a cDNA microarray for detecting and genotyping HRVs based on the 5'NCR and VP4/VP2 target regions.

## **Materials and Methods**

**Virus strains.** Seventeen prototype HRV strains and 15 clinical HRV isolate strains were provided by the Viral and Rickettsial Disease Laboratory at the California Department of Health Services (Richmond, CA).

**Cloning RT-PCR products into plasmid vector.** Previously purified RT-PCR products from the 5'NCR and VP4/VP2 regions were inserted into commercial pCR4TOPO plasmid vector (Invitrogen, Carlsbad, CA) by T/A cloning and introduced into TOP10 *E.coli* (Invitrogen, Carlsbad, CA), as per manufacturer instructions. Bacterial cells were plated on Luria broth agar containing ampicillin and incubated overnight at 37°C. Colonies were subsequently screened by PCR using primers T3 (5'-ATTAACCCTCACTAAAGGGA-3') and T7 (5'-TAATACGACTCACTATAGGG-3').

**Gel electrophoresis.** Five microliters of each PCR product was mixed with 1  $\mu$ l of 6X loading buffer and subjected to 1% agarose gel electrophoresis. The gels were visualized after staining with ethidium bromide.

**Purification and sequencing of PCR products.** Positive PCR products were purified using QIAquick PCR Purification Kit (Qiagen, Valencia, CA). To ensure sequence of insert was correct, PCR products were sequenced in both directions using Sanger dideoxy cycle sequencing method with the ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA) as per manufacturer instructions.

**Microarray spotting.** Aminosilane coated glass slides (Erie Scientific Company, Portsmouth, NH) were spotted with purified PCR products using 100  $\mu$ m ChipMaker Micro Spotting Device (TeleChem International, Inc., Sunnyvale, CA) and microarrayer (courtesy of Relman Lab, Stanford University, Palo Alto, CA). Each sample was spotted in triplicate on two subarrays per slide. Plasmid vector pUC19 was used as a negative control.

**Synthesis and purification of Cy-3 labeled test cDNA.** For each labeling reaction, 5  $\mu$ l of extracted viral RNA was used in the presence of 1  $\mu$ g/ $\mu$ l random hexamer primer, 1 mM Cy3-dUTP (Amersham Biosciences, Pittsburgh, PA), 25 mM dNTPs, 0.1 M DTT, First Strand Buffer (Invitrogen, Carlsbad, CA) and 400 U SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA) and incubated for one hour. After one hour incubation, 200 U of SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA) was added and the reactions were incubated for another hour. Reactions were stopped by adding 0.1 N NaOH and neutralized by adding 0.1 N HCl. Human metapneumovirus was used as a negative control. Labeled cDNA was purified

using MinElute Reaction Cleanup Kit (Qiagen, Valencia, CA) as per manufacturer instructions.

**Hybridization of Cy-3 labeled test cDNA to the microarray.** The test cDNA was applied to the microarray and incubated in a hybridization cassette (TeleChem International, Inc., Sunnyvale, CA) overnight at 65°C. After incubation arrays were removed and washed at room temperature in 2X SSC, 0.03% SDS for approximately 2 min. Microarrays were further washed in 2X SSC, 1X SSC, and 0.2X SSC for 2 min. Subsequently, slides were dried by centrifugation at 25 Gs for 2 min.

**Scanning and analysis of microarrays.** Dried arrays were scanned at 532 nm and images were acquired on a GenePix 4000B Microarray Scanner (Axon Instruments, Union City, CA). Images were aligned and analyzed with GenePix Pro software (Axon Instruments, Union City, CA) based on signal strength.

## Results

Low background and autofluorescence was observed for each tested microarray. No signal was received for microarrays hybridized with the negative control cDNA from human metapneumovirus (data not shown). Unique and selective hybridization pattern was seen for each tested HRV strain (Figure 4) allowing correct identification and subtyping of test cDNA. Stronger signals were seen for spots containing VP4/VP2 RT-PCR products, although results for both 5'NCR and VP4/VP2 regions were in agreement and gave strong signals.

## **Discussion**

High hybridization signals combined with low background indicate that the microarray is highly specific for detecting HRV cDNA. Each test cDNA was correctly subtyped and was in agreement with previous 5'NCR RT-PCR and VP4/VP2 RT-PCR results. There was a strong agreement between VP4/VP2 and 5'NCR results, as expected. The stronger hybridization of test cDNA with VP4/VP2 products on the microarray may be due to the larger fragment size of the VP4/VP2 PCR products. The VP4/VP2 PCR products are approximately 540 nt long, whereas the 5'NCR PCR products are approximately 350 nt long. HRV isolate T03-2119 test cDNA hybridized strongly with spots containing 5'NCR and VP4/VP2 from HRV 36, hence genotyping T03-2119 as HRV36. These results are in agreement with previous RT-PCR based genotyping results.


Our results support the potential use of microarrays for detecting and genotyping HRV in clinical samples. This is the first report using cDNA microarray technology for effective characterization of HRVs. Further evaluation of microarray are required, but these preliminary results indicate that cDNA microarrays can be a highly efficient and high throughput platform for simultaneous detection and genotyping of HRVs.

## **Acknowledgments**

This work is supported by the California Department of Health Services and a National Institutes of Allergy and Infectious Diseases Grant AI-50496 (PPG).

## REFERENCES CITED

1. **Dhiman, N., R. Bonilla, D. J. O'Kane, and G. A. Poland.** 2001. Gene expression microarrays: a 21st century tool for directed vaccine design. *Vaccine* **20**:22-30.
2. **Epstein, C. B., and R. A. Butow.** 2000. Microarray technology - enhanced versatility, persistent challenge. *Curr Opin Biotechnol* **11**:36-41.
3. **Izuhara, K., and H. Saito.** 2006. Microarray-based identification of novel biomarkers in asthma. *Allergol Int* **55**:361-7.
4. **Mehlmann, M., E. D. Dawson, M. B. Townsend, J. A. Smagala, C. L. Moore, C. B. Smith, N. J. Cox, R. D. Kuchta, and K. L. Rowlen.** 2006. Robust sequence selection method used to develop the FluChip diagnostic microarray for influenza virus. *J Clin Microbiol* **44**:2857-62.
5. **Nordstrom, H., K. I. Falk, G. Lindegren, M. Mouzavi-Jazi, A. Walden, F. Elgh, P. Nilsson, and A. Lundkvist.** 2005. DNA microarray technique for detection and identification of seven flaviviruses pathogenic for man. *J Med Virol* **77**:528-40.
6. **Schneider, R. A.** 2007. How to tweak a beak: molecular techniques for studying the evolution of size and shape in Darwin's finches and other birds. *Bioessays* **29**:1-6.
7. **Sengupta, S., K. Onodera, A. Lai, and U. Melcher.** 2003. Molecular detection and identification of influenza viruses by oligonucleotide microarray hybridization. *J Clin Microbiol* **41**:4542-50.
8. **Townsend, M. B., E. D. Dawson, M. Mehlmann, J. A. Smagala, D. M. Dankbar, C. L. Moore, C. B. Smith, N. J. Cox, R. D. Kuchta, and K. L. Rowlen.** 2006. Experimental evaluation of the FluChip diagnostic microarray for influenza virus surveillance. *J Clin Microbiol* **44**:2863-71.
9. **Wang, D., L. Coscoy, M. Zylberberg, P. C. Avila, H. A. Boushey, D. Ganem, and J. L. DeRisi.** 2002. Microarray-based detection and genotyping of viral pathogens. *Proc Natl Acad Sci U S A* **99**:15687-92.
10. **Yao, P. L., M. F. Tsai, Y. C. Lin, C. H. Wang, W. Y. Liao, J. J. Chen, and P. C. Yang.** 2005. Global expression profiling of theophylline response genes in macrophages: evidence of airway anti-inflammatory regulation. *Respir Res* **6**:89.



**Figure 4.** Unique and selective hybridization patterns seen for each test cDNA. A) test cDNA from HRV 4, member of HRV-B. B) test cDNA from HRV 71, member of HRV-A. c) test cDNA from clinical isolate T03-2119, previously genotyped as HRV 36, was correctly subtyped as HRV 36 based on microarray analysis.

## APPENDIXES

#### APPENDIX A. ADDITIONAL REFERENCES


1. **Andries, K., B. Dewindt, J. Snoeks, L. Wouters, H. Moereels, P. J. Lewi, and P. A. Janssen.** 1990. Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity. *J Virol* **64**:1117-23.
2. **Atmar, R. L., and P. R. Georgiou.** 1993. Classification of respiratory tract picornavirus isolates as enteroviruses or rhinoviruses by using reverse transcription-polymerase chain reaction. *J Clin Microbiol* **31**:2544-6.
3. **Bardin, P. G., S. L. Johnston, and P. K. Pattemore.** 1992. Viruses as precipitants of asthma symptoms. II. Physiology and mechanisms. *Clin Exp Allergy* **22**:809-22.
4. **Billaud, G., S. Peny, V. Legay, B. Lina, and M. Valette.** 2003. Detection of rhinovirus and enterovirus in upper respiratory tract samples using a multiplex nested PCR. *J Virol Methods* **108**:223-8.
5. **Boriskin, Y. S., P. S. Rice, R. A. Stabler, J. Hinds, H. Al-Ghusein, K. Vass, and P. D. Butcher.** 2004. DNA microarrays for virus detection in cases of central nervous system infection. *J Clin Microbiol* **42**:5811-8.
6. **Callahan, P. L., S. Mizutani, and R. J. Colonno.** 1985. Molecular cloning and complete sequence determination of RNA genome of human rhinovirus type 14. *Proc Natl Acad Sci U S A* **82**:732-6.
7. **Dagher, H., H. Donninger, P. Hutchinson, R. Ghildyal, and P. Bardin.** 2004. Rhinovirus detection: comparison of real-time and conventional PCR. *J Virol Methods* **117**:113-21.
8. **Deffernez, C., W. Wunderli, Y. Thomas, S. Yerly, L. Perrin, and L. Kaiser.** 2004. Amplicon sequencing and improved detection of human rhinovirus in respiratory samples. *J Clin Microbiol* **42**:3212-8.
9. **Duechler, M., T. Skern, W. Sommergruber, C. Neubauer, P. Gruendler, I. Fogya, D. Blaas, and E. Kuechler.** 1987. Evolutionary relationships within the human rhinovirus genus: comparison of serotypes 89, 2, and 14. *Proc Natl Acad Sci U S A* **84**:2605-9.
10. **Fiala, M., and L. B. Guze.** 1970. The rhinoviruses of man. *Calif Med* **112**:1-6.
11. **Gama, R. E., P. J. Hughes, C. B. Bruce, and G. Stanway.** 1988. Polymerase chain reaction amplification of rhinovirus nucleic acids from clinical material. *Nucleic Acids Res* **16**:9346.

12. **Garbino, J., M. W. Gerbase, W. Wunderli, C. Deffernez, Y. Thomas, T. Rochat, B. Ninet, J. Schrenzel, S. Yerly, L. Perrin, P. M. Soccal, L. Nicod, and L. Kaiser.** 2004. Lower respiratory viral illnesses: improved diagnosis by molecular methods and clinical impact. *Am J Respir Crit Care Med* **170**:1197-203.
13. **Gazina, E. V., D. N. Harrison, M. Jefferies, H. Tan, D. Williams, D. A. Anderson, and S. Petrou.** 2005. Ion transport blockers inhibit human rhinovirus 2 release. *Antiviral Res* **67**:98-106.
14. **Grunstein, M. M., H. Hakonarson, R. Whelan, Z. Yu, J. S. Grunstein, and S. Chuang.** 2001. Rhinovirus elicits proasthmatic changes in airway responsiveness independently of viral infection. *J Allergy Clin Immunol* **108**:997-1004.
15. **Hobson, D.** 1973. Acute respiratory virus infections. *Br Med J* **2**:229-31.
16. **Holgate, S. T.** 2006. Rhinoviruses in the pathogenesis of asthma: the bronchial epithelium as a major disease target. *J Allergy Clin Immunol* **118**:587-90.
17. **Kapikian, A. Z., J. D. Almeida, and E. J. Stott.** 1972. Immune electron microscopy of rhinoviruses. *J Virol* **10**:142-6.
18. **Klinck, R., T. Sprules, and K. Gehring.** 1998. Structural conservation in RNA loops III and VI of the internal ribosome entry sites of enteroviruses and rhinoviruses. *Biochem Biophys Res Commun* **247**:876-81.
19. **Konno, S., K. A. Grindle, W. M. Lee, M. K. Schroth, A. G. Mosser, R. A. Brockman-Schneider, W. W. Busse, and J. E. Gern.** 2002. Interferon-gamma enhances rhinovirus-induced RANTES secretion by airway epithelial cells. *Am J Respir Cell Mol Biol* **26**:594-601.
20. **Kriesel, J. D., and W. A. Sibley.** 2005. The case for rhinoviruses in the pathogenesis of multiple sclerosis. *Mult Scler* **11**:1-4.
21. **Kuypers, J., N. Wright, J. Ferrenberg, M. L. Huang, A. Cent, L. Corey, and R. Morrow.** 2006. Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children. *J Clin Microbiol* **44**:2382-8.
22. **Lehtinen, P., T. Jartti, R. Virkki, T. Vuorinen, M. Leinonen, V. Peltola, A. Ruohola, and O. Ruuskanen.** 2006. Bacterial coinfections in children with viral wheezing. *Eur J Clin Microbiol Infect Dis* **25**:463-9.

23. **Loens, K., M. Ieven, D. Ursi, C. De Laat, P. Sillekens, P. Oudshoorn, and H. Goossens.** 2003. Improved detection of rhinoviruses by nucleic acid sequence-based amplification after nucleotide sequence determination of the 5' noncoding regions of additional rhinovirus strains. *J Clin Microbiol* **41**:1971-6.
24. **Louie, J. K., J. K. Hacker, R. Gonzales, J. Mark, J. H. Maselli, S. Yagi, and W. L. Drew.** 2005. Characterization of viral agents causing acute respiratory infection in a San Francisco University Medical Center Clinic during the influenza season. *Clin Infect Dis* **41**:822-8.
25. **McGregor, S., and H. D. Mayer.** 1968. Biophysical studies on rhinovirus and poliovirus. I. Morphology of viral ribonucleoprotein. *J Virol* **2**:149-54.
26. **McGregor, S., and H. D. Mayor.** 1971. Biophysical and biochemical studies on rhinovirus and poliovirus. II. Chemical and hydrodynamic analysis of the rhinovirion. *J Virol* **7**:41-6.
27. **Pattemore, P. K., S. L. Johnston, and P. G. Bardin.** 1992. Viruses as precipitants of asthma symptoms. I. Epidemiology. *Clin Exp Allergy* **22**:325-36.
28. **Pilipenko, E. V., V. M. Blinov, and V. I. Agol.** 1990. Gross rearrangements within the 5'-untranslated region of the picornaviral genomes. *Nucleic Acids Res* **18**:3371-5.
29. **Pitkaranta, A., M. Starck, S. Savolainen, T. Poyry, I. Suomalainen, T. Hyypia, O. Carpen, and A. Vaheri.** 2001. Rhinovirus RNA in the maxillary sinus epithelium of adult patients with acute sinusitis. *Clin Infect Dis* **33**:909-11.
30. **Poyry, T., L. Kinnunen, and T. Hovi.** 1992. Genetic variation in vivo and proposed functional domains of the 5' noncoding region of poliovirus RNA. *J Virol* **66**:5313-9.
31. **Reischl, A., M. Reithmayer, G. Winsauer, R. Moser, I. Gosler, and D. Blaas.** 2001. Viral evolution toward change in receptor usage: adaptation of a major group human rhinovirus to grow in ICAM-1-negative cells. *J Virol* **75**:9312-9.
32. **Simon, R., M. D. Radmacher, and K. Dobbin.** 2002. Design of studies using DNA microarrays. *Genet Epidemiol* **23**:21-36.
33. **Sperber, S. J., and F. G. Hayden.** 1988. Chemotherapy of rhinovirus colds. *Antimicrob Agents Chemother* **32**:409-19.
34. **Stanway, G., P. J. Hughes, R. C. Mountford, P. D. Minor, and J. W. Almond.** 1984. The complete nucleotide sequence of a common cold virus: human rhinovirus 14. *Nucleic Acids Res* **12**:7859-75.


35. **Turner, R. B.** 2005. New considerations in the treatment and prevention of rhinovirus infections. *Pediatr Ann* **34**:53-7.
36. **Wildsmith, S. E., G. E. Archer, A. J. Winkley, P. W. Lane, and P. J. Bugelski.** 2001. Maximization of signal derived from cDNA microarrays. *Biotechniques* **30**:202-6, 208.

## APPENDIX B. WORKFLOW DIAGRAM FOR RT-PCR



**Figure 5.** Workflow schematic of 5'NCR RT-PCR for detection and genotyping of HRV

## APPENDIX C. WORKFLOW DIAGRAM FOR MICROARRAY



**Figure 6.** Workflow schematic of microarray platform for characterizing HRV

## APPENDIX D. SUMMARY OF RT-PCR RESULTS

**Table 1.** 5'NCR RT-PCR results correlating with VP4/VP2 RT-PCR results.

<b>HRV Isolate ID</b>	<b>HRV Type</b>	<b>HRV Isolate ID</b>	<b>HRV Type</b>
BMT306	HRV31	T04-2387	HRV28
T02-0106	HRV22	T04-2896	RT-PCR negative
T02-0786	HRV31	T04-3190	HRV70
T02-0928	RT-PCR negative	T04-3247	HRV7
T02-0968	RT-PCR negative	T04-3462	RT-PCR negative
T02-1301	RT-PCR negative	T04-3552A	HRV33
T02-2397	HRV42	T04-3552B	HRV33
T02-2433	HRV47	T04-3607	HRV72
T02-2476	HRV47	T04-3641	HRV29
T02-2477	RT-PCR negative	T04-3642	HRV29
T02-2616	HRV34	T04-3643	HRV29
T02-2857	HRV39	T04-3644	HRV29
T03-0037	HRV49	T04-3645	HRV29
T03-0053	HRV Hanks	T04-3738	HRV61
T03-0066	RT-PCR negative	T04-3747	HRV91
T03-0078	HRV87	T04-3900	RT-PCR negative
T03-0599	HRV47	T04-3901	RT-PCR negative
T03-0600	HRV47	T04-3903	HRV48
T03-0634	HRV47	T04-3906	HRV44
T03-0655	HRV95	T04-3933	HRV7
T03-1753	HRV47	T04-3934	HRV44
T03-1808	HRV39	T04-3935	RT-PCR negative
T03-2119	HRV36	T04-3936	RT-PCR negative
T03-2151	HRV55	T04-3937	RT-PCR negative
T03-2430	HRV94	T04-3938	RT-PCR negative
T03-2431	HRV94	T04-3939	HRV44
T03-2434	HRV47	T04-4103	HRV2
T03-3194	HRV44	T04-4113	RT-PCR negative
T03-3596	HRV65	T04-4310	HRV49
T03-4111	HRV47	T05-0000	HRV46
T03-4112	HRV47	T05-1262	HRV38
T03-4196	HRV1B	T05-1430	HRV22
T03-4311	HRV94	T05-1688	HRV29
T03-4474	HRV47	T05-1738	HRV76
T03-4481	HRV82	T05-1746	RT-PCR negative
T04-0424	HRV1B	T05-2142	HRV19
T04-0714	HRV56	T05-2181	HRV19
T04-0946	HRV16	T05-AAAA	HRV13
T04-0964	HRV43	V06T01884	HRV9
T04-1004	HRV28	V06T01895	HRV52

**Table 1 (cont'd).** 5'NCR RT-PCR results correlating with VP4/VP2 RT-PCR results.

HRV Isolate ID	HRV Type	HRV Isolate ID	HRV Type
T04-1325	HRV75	V06T01974	HRV65
T04-1411	HRV59	V06T02157	HRV8

**Table 2.** 5'NCR RT-PCR results that do not correlate with VP4/VP2 RT-PCR results.

RV Isolate	5'NCR RT-PCR	VP2/VP4 RT-PCR
V06T01482	HRV88	HRV63

**Table 3.** 5'NCR RT-PCR positive isolates that were VP4/VP2 RT-PCR negative.

RV Isolate	5'NCR RT-PCR	VP2/VP4 RT-PCR
BMT303	Positive, untypable	RT-PCR negative
T03-2433	HRV47	RT-PCR negative
T03-3195	HRV44	RT-PCR negative
T05-1034	HRV58	RT-PCR negative
T05-1161	HRV22	RT-PCR negative
T05-1169	Human enterovirus 71	RT-PCR negative
T05-1711	HRV58	RT-PCR negative
T05-2094	HRV43	RT-PCR negative
V06T03226,7	HRV52	RT-PCR negative
V06T04424	HRV44	RT-PCR negative
V06T0477	HRV88	RT-PCR negative
V06T05509	HRV54	RT-PCR negative

## APPENDIX E. EXPANDED LABORATORY PROTOCOLS

### First strand cDNA synthesis

- I. Add 1  $\mu$ l of 50-250 ng random hexamer primer, 1 ng - 5  $\mu$ g total RNA, 1  $\mu$ l dNTP Mix (10 mM each), and sterile, distilled water to 12  $\mu$ l.
- II. Heat mixture to 65°C for 5 min and quick chill on ice. Collect contents of tube by brief centrifugation and add 4  $\mu$ l of 5X First-strand Buffer, 2  $\mu$ l of 0.1M DTT and incubate at 42°C for 2 minutes.
- III. Add 1  $\mu$ l (200 U) of SuperScript II RT and mix by pipetting gently up and down.
- IV. Incubate at 42°C for an hour.
- V. The cDNA can be used as template for amplification in PCR.

### Polymerase chain reaction

- I. Add following to PCR tube:

10X Buffer	5 $\mu$ l
Forward Primer	1 $\mu$ l
Reverse Primer	1 $\mu$ l
10 mM dNTPs	1 $\mu$ l
Ultra pure water	40 $\mu$ l
Taq polymerase	0.2 $\mu$ l
PFU polymerase	0.5 $\mu$ l
cDNA template	2 $\mu$ l

- II. Mix gently and heat reaction to 95°C for 2 min to denature.
- III. Perform 40 cycles of PCR as follows
  - a. 95°C – 15 s
  - b. 50°C – 15 s
  - c. 72°C – 1 min

### Gel electrophoresis

- I. Prepare 1 % agarose gel and set up electrophoresis unit.
- II. Prepare samples (5  $\mu$ l product with 1  $\mu$ l of 6X loading buffer).
- III. Load samples (~6  $\mu$ l per lane). Load 10  $\mu$ l KB+ ladder into reference lanes.
- IV. Run gel at 80V for ~1 hour using 1X TAE buffer.
- V. After run, stain gel with EtBr for 5 min, destain with DI H<sub>2</sub>O for 10-15 minutes.
- VI. Capture image. Purify any amplification product for sequencing.

### **Cloning purified RT-PCR products into electrocompetent TOP10 *E. coli***

- I. Mix following reagents in sterile microfuge tube

Purified RT-PCR Product	4 µl
Dilute salt solution	1 µl
H <sub>2</sub> O	2 µl
pCR4TOPO vector plasmid	1 µl

- II. Mix gently and incubate for 5 minutes at room temperature.  
III. Place reaction on ice until ready for transformation.

### **Transformation of electrocompetent TOP10 *E. coli***

- I. Mix together in labeled sterile 2.5 ml capped tube. Mix gently by tapping side of tube. Keep on ice.

Cloned product	2
TOP10 <i>E. coli</i>	25
H <sub>2</sub> O	13

- II. Add mixture to 0.1 cm cuvette. Have 900 µl media (S.O.C or LB) ready.  
III. Electroporate by pulsing at 1.8 kV, 25µF, and 200 ohms.  
IV. Immediately add media, mix, and transfer all the cells to culture tube.  
V. Incubate in shaker at 37°C for about one hour.  
VI. Plate 10-50 µl of each sample onto pre-warmed selective plates. Incubate overnight.  
VII. Select about 10 colonies for screening by PCR by mixing with sterile saline.

### **Screening colonies for cloned vector by PCR**

- I. Add following to PCR tube:

10X Buffer	5 µl
Forward Primer	1 µl
Reverse Primer	1 µl
10 mM dNTPs	1 µl
Ultra pure water	40 µl
Taq polymerase	0.2 µl
PFU polymerase	0.5 µl
Cells from colony	1 µl

- II. Mix gently and heat reaction to 95°C for 2 min to denature.  
III. Perform 40 cycles of PCR as described above.

## **Expanding positive clones for plasmid prep**

- I. Add ~10 ml of selective media into sterile culture tube.
- II. Add 50 µl of culture from positive saline
- III. Incubate overnight in shaker at 37°C.
- IV. Aliquot 0.8 ml of culture and freeze in 0.2 ml 75% glycerol as stock.
- V. Rest of the culture can be centrifuged (8000 Gs for 10 minutes) and used for plasmid prep as per manufacturer's instructions.

## **Preparing fluorescently labeled cDNA probe**

- I. To anneal primers, mix following in thermocycler tube

Total RNA	50 - 100 µg
Random Hexamer	4 µg
ddH <sub>2</sub> O	to 15.4 µl

- II. Heat mixture to 65°C for 10 minutes and cool on ice
- III. Add 14.6 µl of following mixture to each reaction tube

5X First Strand Buffer	6 µl
0.1M DTT	3 µl
Cy3 (1mM)	3 µl
Unlabeled dNTPs*	0.6 µl
Superscript II (200 U/µl)	2 µl

- IV. Incubate 42°C for 1 hour.
- V. Add 1 µl of SSII (RT booster). Incubate 42°C for 1 hour.
- VI. Degrade RNA and stop reaction by adding 15 µl of 0.1N NaOH.
- VII. Incubate at 70°C for 30 min.
- VIII. Neutralize by adding 15 µl of 0.1N HCl

\* Unlabeled dNTPs:

dATP (25 mM)
dCTP (25 mM)
dGTP (25 mM)
dTTP (10 mM)

### **Probe clean-up**

- I. Add 230  $\mu$ l of Qiagen Buffer PBI to fluorescent labeled cDNA. Mix well by pipetting.
- II. Add mixed contents to a Qiagen MinElute column and spin for 1 minute at 10,000 g. Discard flow-through.
- III. Add 750  $\mu$ l of Qiagen Buffer PE to column and spin for 1 minute at 10,000 g. Discard flow-through
- IV. Spin for 1 minute at maximum speed to remove residual wash buffer
- V. Place column in a clean tube and add 12  $\mu$ l of H<sub>2</sub>O to the center of filter. Incubate 2 minutes at room temperature
- VI. Spin for 1 minute at maximum speed to elute

### **Prehybridization**

- I. UV cross-link printed DNA onto glass substrate with 65 mJ of energy in Stratalinker (650 x 100 $\mu$ J) and transfer arrays on a slide rack.
- II. Prepare prehybridization buffer (5X SSC, 0.1 mg/ml BSA, 0.1% SDS)

ddH <sub>2</sub> O	300 ml
20X SSC	100 ml
10 mg/ml BSA	4 ml
10% SDS	4 ml
- III. Flood slide with prewarmed (42°C) prehybridization buffer (5X SSC, 0.1mg/ml BSA, 0.1% SDS) for 1 hour
- IV. Rinse arrays in 0.1X SSC for 5 minutes at room temperature
- V. Transfer arrays to MilliQ water and incubate at room temperature for 30 seconds
- VI. Wash once more in 0.1X SSC for 5 minutes at room temperature
- VII. Transfer arrays to MilliQ water and incubate at room temperature for 30 seconds
- VIII. Dry arrays and use same day

### **Hybridization of Cy-3 labeled test cDNA with microarray**

- I. Measure probe volume with pipettor and add water to bring volume to 14.8  $\mu$ l.
- II. Add 2.7  $\mu$ l 20X SSC. Mix well.
- III. Add 0.54  $\mu$ l of 10% SDS and mix well. Centrifuge briefly to collect entire volume to the bottom of the tube.
- IV. Prepare hybridization chamber by adding 20  $\mu$ l of 3X SSC to each reservoir.
- V. Place 18  $\mu$ l of prepared probe off center on the array and cover gently with coverslip. Place slide into hybridization chamber.
- VI. Tightly secure hybridization chamber and place in 65°C water bath overnight.

## **Washing arrays after hybridization**

I.      Prepare Wash Solutions:

Solution #1: 200 ml (2X SSC, 0.03% SDS)

Solution #1B: 200 ml (2X SSC)

Solution #2: 200 ml (1X SSC)

Solution #3: 200 ml (0.2X SSC)

- II.     Remove hybridization chamber from water bath and extract slide and immediately submerge into Solution #1, tilting and allowing the coverslip to slide off. Wash slides by agitation for 2 min.
- III.    Remove each slide and wash in Solution #2 for 2 min.
- IV.    Remove each slide and wash in Solution #3 for 2 min.
- V.    Spin dry by centrifugation in a slide rack at 25 Gs for 2 min.
- VI.   Scan arrays at 532 nm (Cy3) immediately.

## APPENDIX F. LIST OF 5'NON-CODING REGION SEQUENCES

### >HRV3 5'NCR

TATCCGCCAACCAACTACGTAAAAGCTAGTAGTATTATGTTTAACTAGGCG  
TTCGATCAGGTGGATTCCCCCTCCACTAGTTGGTCATGAGGCTAGGAATTC  
CCCACGGGTGACCGTGTCTAGCCTGCGTGGCGGCCAACCCAGCTATGCTG  
GGACGCCTTTATAGACATGGTGTGAAGACTCGCATGTGCTTGGTTGTGATT  
CCTCCGGCCCCCTGAATGCGGCTAACCTAACCCCTGGAGCCTGTGTCACAAAC  
CAGTGATGATAAGGTCGTAATGAGCAATTCCGGACGGGACCGACTA

### >HRV4 5'NCR

TATCCGCCAATCAACTACGTAAACGGCTAGTATCATCTTGCTTTGATTGGTG  
TTCGATCAGGTGGTATCCCCACTAGTCTGGTCATGAGGCTAGGAATCCCC  
ACGGGCACCCTGTCTAGCCTGCGTGGCGGCCAGCCCAGCTTGCTGGGA  
CGCCTTTCAAAGACATGGTGTGAAGACCTGCATGTGCTTGGTTGTGAGTCCT  
CCGGCCCCCTGAATGCGGCTAACCTAACCCCTGGAGCCCAGCAGCATAATCCA  
ATGTTGTTGGTCGTAATGAGCAATTCCGGACGGGACGCAGT

### >HRV5 5'NCR

TATCCGCCAGCTAACTGCGAGAAGACTAGTAACACCATGTTGTTTAGACG  
TTCGATCAGGTGAATAACCCATTCACTAGTTGGTCATGAGGCTGAGAATAC  
CCCACAGGTAACTGTGTCAGCCTGCGTGGCGGCCAACCCAGCTATGTCG  
GGACGCCTACTAATAGACATGGTGTGAAGACCTATTGCGCTTAGTTGTGAGT  
CCTCCGGCCCCCTGAATGCGGCTAACCTAACCCCGAGCCTGTGGTGTAAA  
CCAACATTGCAAGGTCGTAATGAGTAATTCTGGATGGGACCGACTA

### >HRV8 5'NCR

TATCCGCAAGATGCCTACGCAAAGCTTAGTAACACTTGGAAAGATTATGGCT  
GGTCGTTCCACTATAACCCATAGTAGACCTGGCAGATGAGGCTAGAAATACC  
CCACTGGTGACAGTGTCTAGCCTGCGTGGCTGCCTGCGCACCCCTATGGGTGC  
GAAGCCATACATTGGACAAGGTGTGAAGAGCCCCGTGTGCTCATCTTGAGTC  
CTCCGGCCCCCTGAATGTGGCTAACCTAACCCCGAGCCAGTGCACACAATC  
CAGTGTGTTTGGTCGTAATGAGTAATTGTGGATGGGACCAACT

### >HRV9 5'NCR

TATCCGCAAAGCGCCTACGCAAAGCCTAGTAACATCTGGAAGTTGCTGGTT  
GGTCGCTCCGCCATATCCCATGGTAGACCTGGCAGATGAGGCTAGAAATTCC  
CCACTGGTGACAGTGTCTAGCCTGCGTGGCTGCACACCCCTGGGTGT  
GAAACCAAGTAATGGACAGGGTGTGAAGAGCCCCGTGTGCTCGCTTGAGTC  
CTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGAGCTAGGGCACACAATC  
CAGTGTGTTCTAGTCGTAATGAGCAATTGCGGGATGGGACATTGG

**>HRV10 5'NCR**

TACCCGCAAGGTGCCTACGCAAAGCCTAGTAACCCCTGAACGATGTGTGGT  
TGGTCGTTGGCTGTACCCCACAGTAGACCTGGCAGATGAGGCTAGATGTT  
CCCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCGCACTCTGAGTG  
CGAAGCCATACTTGACAAGGTGTGAAGAGCCCCGTGTGCTCACCTGAGT  
CCTCCGGCCCTGAATGTGGCTAACCTAACCTGCAGCTAGTACATGCAATC  
CAGCATGCGAGCTAGTCGTAACGAGCAATTGCGGGACGGGACAA

**>HRV11 5'NCR**

TATCCGCAAAGCAACTACGCAAAGCCTAGTATCACTTTGAGAGTATGTGGTT  
GGTCGCTCCACTATAAACCCAATAGTAGACCTGGCAGATGAGGCTAGAACGTC  
CCCCACTGGTAACAGTGTCTAGCCTGCGTGGCTGCCTGCGTCCTCTGGTAG  
GCACGAAGCCATATATTGACAAGGTGTGAAGAGCCCCGTGTGCTTGCTT  
AGTCCTCCGGCCCTGAATGTGGCTAACCTAACCTGCAGCTAGTGTGCATA  
ATCCAATGCATGGCTAGTCGTAATGAGCAATTGCGGGATGGGACCAAC

**>HRV12 5'NCR**

TATCCGCAAGGTGCCTACGAGAAGCCTAGTAATGCTCAAGATGTGGTTGAC  
TGGTCGCTCCGCTGTTCCCCACAGTAGACCTGGCAGATGAGGCTGGACATT  
CCCCACCAGCGATGGTGGTCCAGCCTGCGTGGCTGCCTGCACACCCCTATGGGT  
GTGAAGNCAAATTACTGACAGGGTGTGAAGAGCCTATTGTGCTCACCTGA  
TTCCTCCGGCCCTGAATGTGGCTAACCTAACCCGCTGCTATTGCACACGA  
ACCAGTGTGTAGATAGTCGTAATGAGCAATAGTGGGATGGAACCAACTAT

**>HRV13 5'NCR**

TACCCGCAAGGTGCCTACACAGAACTTAGTACCAATTCTGGAAAATTCTGGCT  
GGTCGCTCAGTTACTACCCAGTAATAGACCTGGCAGATGGGGCTAGAACGTT  
CCCCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCCTCTGG  
GTGTGAAGCCTAGAATTGGACAGGGTGTGAAGAGTCGCGTGTGCTCATCTG  
AGTCCTCCGGCCCTGAATGCGGCTAACCTAACCTGCAGCCATTGCCAC  
AACCCAGTGGGTCTATGGTCGTAATGAGCAATTGCGGGATGGGACCGAC

**>HRV15 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAATGCTTCGAAGTCATTGGTT  
GGTCGCTCCGCTGTAACCCACAGTAGACCTGGCAGATGAGGCTAGAAACTCC  
CCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCCTTGGGTGT  
GAAGCCAAATTACGGACAAGGTGTGAAGAGCCCCGTGTGCTACTTGTAGTC  
CTCCGGCCCTGAATGTGGCTAACCTAACCTGCAGCTAGAGTCACAAATC  
CAGTGTATTCTAGTCGTAATGAGCAATTGCGGGATGGGACAA

**>HRV18 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAGCACTTGAAATAGCATGTGGT  
TGGTCGCTCCACTATTCCCCATAGTAGACCTGGCAGATGAGGCTAGAAATCC  
CCCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCAGCTACGGAC  
ACGAAGCCATATGTTGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAG  
TCCTCCGGCCCCGAATGTGGCTAACCTAACCTGCAAGCTGGGGCATACAA  
TCCAGTGTGAACTCAGTCGAATGAGCAATTGCGGGATGGGACCA

**>HRV19 5'NCR**

TATCCGCAAGGTGCCTACGCAAAGCCTAGTAGCGCTTTGAAATTGTTGGTT  
GGTCGCTCAAGTACAAACCCAGTACTAGACCTGGCAGATGAGGCTAGAAAAC  
CCCCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCATTGGG  
TGTGAAGCCAACACGGACAGGGTGTGAAGAGGCCACGTGTGCTCATCTTGA  
TTCCCTCCGGCCCCCTGAATGCGGCTAACCTAACCTGCAAGCCATTGCTCACAA  
TCCAGTGANAGTTGGTGGTCGAATGAGCAATTGCGGGATGGGACCGACA

**>HRV20 5'NCR**

TGATCCGCGAAAGCAACTACGCAAAGCCTAGTACCATTGATGATGTGTG  
GTTGGTCGTTCCACTATGAACCCGATAGTAGACCTGGCAGATGAGGCTAGAA  
ATTCCCCACTGGCAACAGTGTCTAGCCTGCGTGGCTGCCTGCGTACCCCTG  
TGGGTACGAAGCCATACATTGACAAGGTGTGAAGAGCCCCGTGTGCTTGCT  
TTGAGTCCTCCGGCCCCCTGAATGTGGCTAACCTAACCTGCAAGCTAGTGTG  
ACAATCCAGTACATAGCTAGTCGAATGAGCAATTGCGGGATGGGACCA

**>HRV22 5'NCR**

TACCCGCAAGATGCCTACGCAAAGCTTAGTAACATCTCGAAGATACTTAGTT  
GGTCGCTCATGTGCAACCCAGCACTAGACCTGGCAGATGAGGCTAGAAATT  
CCCCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCCTAACGG  
GTGTGAAGCCCAGTATTGGACAAGGTGTGAAGAGCCCCGTGTGCTCATCTG  
AGTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCTGCAAGCCATTGCTCACAA  
ACCCAGTGANAGTCTATGGTCGAATGAGCAATTGCGGGATGACCG

**>HRV23 5'NCR**

TATCCGCAAGGCGCCTACACAAAGCTTAGTAGCATTCTGAAAGTTGTCTGGTT  
GGTCGTTCCACCATTCCTGGTAGACCTGGCAGATGAGGCTAGAAACTCC  
CCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCCTGGGTGT  
GAAGCCATACGATGGACAGGGTGTGAAGAGCCCCGTGTGCTCGCTTGAGTC  
CTCCGGCCCCCTGAATGTGGCTAACCTAACCTGCAAGCTAGAGCACACAATC  
CAGTGTGTTCTAGTCGAATGAGCAATTGCGGGACGGGACAAGGT

**>HRV24 5'NCR**

TATCCGCAAAGCAAATACGCAAAGCCTAGTAGCATTGGAGAGTATGTGG  
TTGGTCGCTCCACTATAAACCAATAGTAGACCTGGCAGATGAGGCTAGAAA  
TTCCCCACTGGTAACAGTGTCTAGCCTGCGTGGCTGCCTGCGTGCCTTGT  
GAGCACGAAGCCATATAATTGACAAGGTGTGAAGAGCCCCGTGTGCTGCTT  
TGAGTCCTCCGGCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGCGTGT  
CAATCCCAGTACAAAGCTAGTCGTANTGAGCAATTGCGGGATGAC

**>HRV25 5'NCR**

TAACCGCAAAGTGAACCGCAAAGCTTAGTAATGCCTGAAGAATTATGAC  
TGGTCGTTCCGCTATAACCCCTAGTAGACCTGGCAGATGAGGCTAGAAATAC  
CCCACTGGTAACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCCTTCGGGT  
GTGAAGCCATATAATTGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAG  
TCCTCCGGCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTGTATGTAAT  
CCAACATATGGCTAGTCGAATGAGCAATTGCGGGATG

**>HRV26 5'NCR**

TATCCTGCCAACCAACTACGAGGACGGCTAGGTAAATATCATGTTGTCTTGA  
GCGTTCGATCAGGTGAATTCCCCATTCACTAGTTGGTCATGAGGCTGAGAA  
CTCCCCACAGGTGACTGTGTCTAGCCTGCGTGGCGGCCAACCCAGCCACGG  
CTGGGACGCCACTGATAGACATGGTGTGAAGACCCAATTGTGCTTGGTTGT  
GACTCCTCCGGCCCTGAATGCGGCTAACCTAACCCGGAGCCTGTAGTGT  
AAGCCAACACATACAAGGTGTAATGGGCAACTCTGGGACGGGACCGA

**>HRV27 5'NCR**

TATCCGCCAATCAACTACGTAATGGCTAGTATTACCATGTTGTACTGGTG  
TTCGATCAGGTGGTCCCCCCTAGTTGGTCATGAGGCTAGGAACCTCCCC  
ACGGGTGACCGTGTCTAGCCTGCGTGGCGGCCAACCCAGCTTGCTGGGA  
CGCCTTTTACAGACATGGTGTGAAGACCTGCATGTGCTTGATTGTGAGTCCT  
CCGGCCCTGAATGCGGCTAACCTAACCCGGAGCCTGTCAACATAATACC  
AATGTTGTTGAGGTGTAATGAGTAATTCCGGATGACCG

**>HRV28 5'NCR**

TATCCGCAAAGATGCCTACGCAAAGCTTAGTACCAACCTCGATTCTATTGGTT  
GGTCGTTAGCTACAAAACCCAGTAGTAGACCTGGCAGATGAGGCTAGAAAT  
ACCCCACGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCATGG  
GTGTGAAGCCAATTAGTTGACAAGGTGTGAAGAGCCCCGTGTGCTCATCTG  
ATTCCCTCCGGCCCTGAATGTGGCTAACCTAACCTGCAGCCAATGTACACA  
ATCCAGTGTATTATTGGTCGTAATGAGTAATTGCGGGATGACA

**>HRV30 5'NCR**

TACCCGCAAAGTGCCTACGCAAAGCCTAGTAGCACTTTAGAAGTTGTCTGGC  
TGGTCGCTCCGCCATTCCCCCTGGTAGACCTGGCAGATGAGGCTAGAAATAC  
CCCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCACACCCATGGGTG  
TGAAGCCATACAATGGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGGGCACACAAT  
CCAGTGTGTATCTAGTCGTAATGAGCAATTGCGGGACGGGACCAACTATG

**>HRV31 5'NCR**

TACCCGCAAAGTGCCTACGCAAAGCTTAGTAATATCTTGAACGATATAATGGTT  
GGTCGCTCCACTAATCCCCATAGTAGACCTGGCAGATGAGGCTGGAAACTCC  
CCACTGGCGACAGTGTCCAGCCTGCCTGGCTGCCTGCACACTCACCGAGT  
GCGAAGCCATATATTGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAG  
TCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTCATACAAA  
CCAGTATGTGGCTAGTCGTAATGAGCAATTGCGGGACGGGACAAT

**>HRV32 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAACTACCTCGAAAGTACTTGAC  
TGGTCGCTCCGCCATACCCATGGTAGACCTGGCAGATGAGGCTAGAAATCC  
CCCACTGGTGACAGTGTCTAGCCTGCCTGGCTGCACACCCATTGGGTG  
TGAAGCCAAGTAATGGACAGGGTGTGAAGAGTCGAGTGTGCTCACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGGGCACACAAT  
CCAGTGTGTATCTAGTCGTAATGAGCAATTGCGGGATGGGACCACAT

**>HRV33 5'NCR**

TATCCGCAAAGACAACACTACGCAAAGCCTAGTATCATCTTGAAAGTATGTGGTT  
GGTCGCTCCGCTATAAACTCAATAGCAGACCTGGCAGATGAGGCTAGAAACT  
CCCCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCCTGCCTACGG  
GTACGAAGCCATATATTGACAAGGTGTGAAGAGCCCCGTGTGCTTGTCTTG  
AGTCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTGGTATGCACA  
ATCCAGTACATGCCAGTCGTAATGAGCAATTGCGGGATGGGACATT

**>HRV34 5'NCR**

TATCCGCAAAGGCGCCTACACAAAACCTAGTAACATCTTGAATGGTATGTGGC  
TGGTCGTTCCGCTAAACCCATAGTAGACCTGGCAGATGAGGCTAGAAATTC  
CCCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCCTGCCTACCGA  
CACGAAGCCATATACTTGACAAGGTGTGAAGAGTCGGTGTGCTCGTCTGA  
GTCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCCAGTGCACACA  
AACCAGTGTGTAGCTGGTCGTAATGAGTAATTGCGGGATGGGACAATT

**>HRV35 5'NCR**

TACCCGCCAACCAACTACGTAACGGCTAGTAACACCATTGAATTGTCTTGAC  
GTTCGATCAGGTGGTAACCCCCACTAGTTGGTCATGAGGCTGAGAACTC  
CCCACGGGTAAACCGTGTCTCAGCCTGCCTGGCGGCCAACCCAGCTCTGCTG  
GGACGCCAATTCAATTGACATGGTGTGAAGACCTGCATGTGCTGGTTGTGATT  
CCTCCGGCCCTGAATGCGGCTAACCTAACCCGGAGCCACGCCATATA  
TNCAACAATGTCGTATGGTCGTA

**>HRV36 5'NCR**

TATCCCCACACTGCCTACACAGAGCCTAGTACCACTTTGATGTAATTAGGTT  
GGTCGCTCCCTGCAAACCCAGCAGTAGACCTGGCAGATGAGGCTGGACACTC  
CCCACTGGTACAGTGGTCCAGCCTGCCTGGCTGCCTGCACCCCTATTGGGT  
GAGAAGCCTACTTATTGACAAGATGTGAAGAGGCCGCGTGTGCTCAGTGTGCT  
TCCTCCGGCCCTGAATGTGGCTAACCTAACCCCTGCAGCCGCTGCCATAAT  
CCAATGGGTTACGGTCGTAACGCGCAAGTGCAGGGATGGACAC

**>HRV38 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAACACACTTGAAAGGTCTATGGT  
TGGTCGTTAGCTAAACCCATAGTAGACCTGGCAGATGAGGCTAGAAATT  
CCCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCCTGCACACCCCTACGGGT  
GTGAAGCCATATACTCGACAAGGTGTGAAGAGGCCGCGTGTGCTCACTTGAG  
TCCTCCGGCCCTGAATGTGGCTAACCTAACCCCGAGCTAGTCATACAA  
ACCAGTATGTGGCTAGTCGTAATGAGCAATTGTGGGATGGGACCAACTT

**>HRV40 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAGCAGCTTAAAGGTTATGGT  
TGGTCGTTAGCTAAACCCCTAGTGGACCTGGCAGATGAGGCTAGAAAGTAC  
CCCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCCTGCACACCCCTATGGGT  
GTGAAGCCATATAATTGACAAGGTGTGAAGAGGCCGCGTGTGCTCACTTGAG  
TCCTCCGGCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTCATGTAAT  
CCAACATGTTGCTAGTCGTAATGAGCAATTGCAGGGATGGGACCAACTAC

**>HRV41 5'NCR**

TATCCGCAAGATGCCTACGCAGAACCTAGTATCACACTGGAAAGATTCTCGGT  
TGGTCGCTCAGTTACAACCCAGTAACAGACCTGGCAGATGAGGCTAGAAAT  
TCCCCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCCTGCACACCCGTTGG  
GTGTGAAGCCTAGAATTGGACAGGGTGCAGAGTCGAGTGTGCTCATCTTG  
AGTCCTCCGGCCCTGAATGCGGCTAACCTAACCCCTGCAGCCATTGCCAC  
AAACCAGTGGGTCTATGGTCGTAATGAGCAATTGCAGGGATGGGACCGACT

**>HRV42 5'NCR**

TATCCGCCAGTTAACTGCGAAAAGACTAGTAACATCATGCACATTCTAGGG  
TGTCGATCAGGTGAAAACCCCATTCACTAGTTGGTCATGAGGCTGANAG  
TACCCCACAGGCAGTGTCTAGCCTGCGTGGCGGCCAACCGACTTATG  
TCGGGACGCCTATTAAATAGACATGGTGTGAAGATCCTATTGCCTAGCTGTG  
AGTCCTCCGGCCCTGAATGCGCTAACCTAACCCGGAGTCTGTGATGTA  
AGCCAACATTGCAAGGTCGTAATGAGTAATTCTGGGATGGGACCGACT

**>HRV43 5'NCR**

TATCCGCAAGATGGCCTACACAGAGCCTAGTAACATTCTAGAAAAATTCTGG  
TTGGTCGCTCAATTGCAAACCCAGCAATAGACCTGGCAGATGAGGCTGGACA  
TTCCCCACTGGCGACAGTGGTCCAGCCTGCGTGGCTGCCTGCACACTCCTTG  
GAGTGTGAAGCCATAATTGGACAGGGTGCAGAGGCGCGTGTGCTCATCT  
TGAGTCCTCCGGCCCTGAATGCGGCTAACCTAACCTGCAGCCATTGTTG  
CAATCCCAGCAGATATGGTCGTAATGAGCAATTGCGGGATGACCG

**>HRV44 5'NCR**

TATCCGAAAATGACTACGCAAAGCCTAGTAATATCTTGAAGGACTTATGGT  
TGGTCGCTCCACTAAACCCATAGTAGACCTGGCAGATGAGGCTAGAAATAC  
CCCACTGGAGACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCATGGGT  
GTGAAGCCATACTTCGACAAGGTGTGAAGAGCCCCGTGTGCTCATTGAGT  
CCTCCGGCCCTGAATGTGGCTAACCTAACCTGCAGCTAGTCATGCAATC  
CAGCATGTTGCTAGTCGTAACGAGCAATTGCGGGATGGGACCAACTACT

**>HRV45 5'NCR**

TATCCGACAATTACTACACAAAGCCTAGTAATATCTTGTATAAGCTCTTGGT  
TGGTCGTTAGCTGTTACCCCCAGTAGACTGGCAGATGAGGCTGGGTGTTCC  
CCACTGGCGACAGTGACCCAGCCTGCGTGGCTGCCTACACACCTGGTACAG  
GTGTGAAGCCAAAAGTGGACAAGGTGTGAAGAGCCCCGTGTGCTAATTGTGA  
TTCCTCCGGCCCTGAATGCGGCTAACCTAACCCATAGCCAATGCATGTAA  
ACCAACATGTATTGGTCGTAACGGTAACGGTAACGTGGGACGGAACCGACTA

**>HRV46 5'NCR**

TATCCGAAAATGCCTACACAAAGCCTAGTATCATCTTGAAGGCACAGAGT  
TGGTCGCTCCACTATTCCCCATAGTAGACCTGGCAGATGAGGCTAGAAAATC  
CCCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCCTGCAGG  
ACGAAGCCCTGTGTTGACAAGGTGTGAAGAGCCCCGTGTGCTCATTGATT  
CCTCCGGCCCTGAATGTGGCTAACCTAACCTGCAGCTAGTCACACAAA  
CCAGTGTGTATCTAGTCGTAATGAGTAATTGCGGGACGGGACCAATATG

**>HRV47 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCTTAGTAACATCTGAATGATATATGGTT  
GGTCGTTCCACTAAACCCCAGTAGACCTGGCAGATGAGGCTGGAAATTCC  
CCACTGGCGACAGTGTCCAGCCTGCGTGGCTGCCTGCGCACTCTATGAGTG  
CGAAGCCATATATTGACAAGGTGTGAAGAGCCCCGTGCTCACTTGAGT  
CCTCCGGCCCTGAATGTGGCTAACCTAACCTGCAGCTAGTCATAACAATC  
CCAGTGTGTAGCTAGTNCGTAATGAGCAATTGCGGGATGACA

**>HRV48 5'NCR**

TACCCGCCAGTTAACTACACAAACAGCTAGTAACATCTTGTGTTAGGGCG  
TTCGATCAGGTGAGTTACCCCCCTCACTAGTCTGGTCGATGAGGCTGAGAAAT  
CCCCACGGGTGACCGTGTCTCAGCCTGCGTGGCGGCCAGCCCAGCTTATGCT  
GGGACGCCTTAAGTATGACATGGTGTGAAGAGACTCGCGTGTGCTTAGCTGTGA  
GTCCTCCGGCCCTGAATGCGGCTAACCTAACCCCCGGAGCCTTGAGGCACA  
ATCCAGTGCCCGCGAGGTCGTAACGAGAAATTCTGGGACGGGACA

**>HRV49 5'NCR**

TATCCGCAAAGCGCCTACGCAAAGCCTAGTAACACCTTGAAATTGTTGGTT  
GGTCGTTCCGCCATTTCCTGGTAGACCTGGCAGATGAGGCTAGAAACACC  
CCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCCTGTGGGTGT  
GAAGCCAAATAATGGACAAGGTGTGAAGAGCCCCGTGCTCGCTTGAGTC  
CTCCGGCCCTGAATGCGGCTAACCTAACCTGCAGCTAGAGCACACAAGC  
CAGTGTGTATCTAGTCGTAATGAGTAATTGCGGGACGGGACCGACTATG

**>HRV50 5'NCR**

TATCCGCAAAGCGCCTACGCAAAGCCTAGTAACAGCTCGAAGATTATGGT  
TGGTCGTTCCGCTGTTCCCCACAGTAGACCTGGCAGATGAGGCTAGAGATTCC  
CCACTGGTAACAGTGTCTAGCCTGCGTGGCTGCCTGCGCACACCCCTCGGGTGC  
GAAGCCATATTCGGACAAGGTGCGAAGAGCCCCGTGCTCGCTTGAGTC  
CTCCGGCCCTGAATGTGGCTAACCTAACCTGCAGCTAGTCATAACAAAC  
CAGTATGTGGCTAGTCGTAATGAGCAATTGCGGGATGACA

**>HRV53 5'NCR**

TATCCGCAAAGATGCCTACGCAAAGCTTAGTAGCGCTCTGAATGCTTTGGCT  
GGTTGTTCCACTACAAACCCAGTAGTAAACCTGGCAGATGAGGCTAGAAGTT  
CCCCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCCTATGGGT  
GTGAAGCCAATCAGTTGACAGGGTGTGAAGAGCCCCGTGCTCATCTTGAG  
TCCTCCGGCCCTGAATGTGGCTAACCTAACCCGAGCCAAGGTGTGCAA  
ACCAGCACATTCTTGGTCGTAACGAGTAATTGTGGGATGGGACACATG

**>HRV54 5'NCR**

TACCCGCAAAGTGCCTACGCGAACGCTAGTAACATCTGAAGAATTATGGT  
TGGTCGCTCCACTATTCCCCATAGTAGACCTGGCAGATGAGGCTAGAAATTCC  
CCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCACACCCCTACGGGTG  
TGAAGCCATATATTGACAAGGTGTGAAGAGCCTAGTGTGCTCACTTGAGTC  
CTCCGGCCCCCTGAATGTGGCTAACCTAACCGTAGCTAGTGCATAACATCC  
AGTGTGTGGCTAGTCGTAACGAGCAATTACGGGATGGGACCAACTAC

**>HRV55 5'NCR**

TATCCGCAAGGGATGCCTACGCAAAGTCTAGTAACCCCTTGAAGATATTGGT  
TGGTCGCTCCACTATTCCCCATAGTAGACCTGGCAGATGAGGCTAGAAATTCC  
CCACTGGTGACAGTGTCTAGCCTGCCTGGCTGCACACCCATTGGGTG  
TGAAGCCAATATTGACAAGGTGTGAAGAGCCCCGTGTGCTCATCCTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCGTAGCTAGTGCATGCAATC  
CAGCATGTAGCTAGTCGTAATGAGCAATTGCAGGGATGGGACCAACTA

**>HRV56 5'NCR**

TATCCGCAATGTGCCTACGCAAAGCCTAGTAATATCTTAGATGATATATGGTT  
GGTCGCTCCGCCATTCCCCATGGTAGACCTGGCAGATGAGGCTAGAAAACCTCC  
CCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCCTGCAGCTCTGAGTGC  
GAAGCCATATATTGACAAGGTGTGAAGAGCCCCGTGTGCTCACATTGAATC  
CTCCGGCCCCCTGAATGTGGCTAACCTAACCGTAGCTAGTGCACACAAAC  
CAGTGTGTAGCTAGTCGTAACGAGCAATTGCAGGGATGGGACCAACTACT

**>HRV57 5'NCR**

TATCCGCAAAGTGCCTACACAAAGCTTAGTACCATTTGAGAACTTATGGTT  
GGTCGCTCCGCTGAACCCCACAGTAGACCTGGCAGATGAGGCTAGAAAACCC  
CCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCACACCCCTATGGGTG  
TGAAGCCATATGTTGACAAGGTGCGAAGAGCCCCGTGTGCTCACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCGTAGCTAGTGCACACAAA  
CCAGTGTGTGCTAGTCGTAACGAGCAATTGCAGGGATGGGACCAATTG

**>HRV60 5'NCR**

TACCCGCAAAGTGCCTACGCAAAGCTTAGTAACACTTTGAAGTTACGTGGTT  
GGTCGCTCAGCCAAACCCATGGTAGACCTGGCAGATGAGGCTAGAAGTACC  
CCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCACACCCCTCTGGGTG  
GAAGCCATATAATGGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAGTC  
CTCCGGCCCCCTGAATGTGGCTAACCTAACCGTAGCTAGTGCATGCAATCC  
AGTATGTATCTAGTCGTAATGAGCAATTGCAGGGATGGGACACATGGGG

**>HRV61 5'NCR**

TATCCGCAAGATGCCTACGCAAAGCCTAGTAACACTTGAAGTGTGGTT  
GGTCGCTCAGTTACAACCCCAGTAATAGACCTGGCAGATGAGGCTAGATATC  
CCCCACTGGCGACAGTGATCTAGCCTGCGTGGCTGCCTGCACACCCATTATGG  
GTGTGAAGCCAACATATGACAAGGTGCGAAGAGGCCACGTGTGCTCATCTG  
AGTCCTCCGGCCCTGAATGCGGCTAACCTAACCCCTGCAGCCATTGCTCAC  
AGCCAGTGGGTATGTGGCGTAATGAGAAAATTGCGGGACGGGACCGAT

**>HRV63 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTTAACACTTGAATGTCTATGG  
TTGGTCGCTCAGCTATTCCCCATAGTAGACCTGGCAGATGAGGCTAGAAATA  
CCCCACTGGTAACAGTGTCTAGCCTGCGTGGCTGCCTGCGCACACCCCTCCCGG  
GTGCGAAGCCATATATATGACAAGGTGCGAAGAGGCCCGTGTGCTCACTTG  
AATCCTCCGGCTCCTGAATGTGGCTAACCTAACCCCGCAGCCAGTGCACAT  
AAGCCAATGTGTGGCTGGCGTAATGAGCAATTGTGGGATGGACAAT

**>HRV64 5'NCR**

TACCCGCAAGACGCCAACGCTACGCAAAGCCTAGTAATGCCTTGAAGATATTGTCT  
GGTCACTCAGGTACAATCCCAGTACTAGACCTGGCAGATGAGGCTGGAAAAT  
CCCCACTGGCGACAGTGTTCCAGCCTGCGTGGCTGCCTGCACACCCATACGG  
GTGTGAAGCCAATATTGGACAAGGTGTGAAGAGGCCCGTGTGCTCGTCTTG  
AGTCCTCCGGCCCTGAATGCGGCTAACCTAACCCACAGCCATTGCTTGCA  
TTCCAGCAAGTCTATGGCGTAATGAGCAATTGTGGGATGGGACCGACT

**>HRV65 5'NCR**

TCATCCGCGCAATTACTACGCAAAGCTTAGTAACCTCCAAGAAATTCTTGG  
TTGGCCGTTCCGCTGGTACCCCACCAAGTAGGCTGGCAGATGAGGCTGAGTA  
ATCCCCACTGGCGACAGTGACTCAGCCTGCGTGGCTGCCTACACACCTGGTA  
ACAGGTGTGAAGCCATAGAAAGGACAGGGTGTGAAGAGGCCCGTGTGCTAA  
TTGTGATTCCCTCCGGCCCTGAATGCGGCTAACCTAACCCACATCCAATGCG  
CATAGCCAATGCGTATTGGCGTAATGGGCAACTGTGGGACCGAACCG

**>HRV66 5'NCR**

TATCCGCAAGGTGCCTACGCAAAGCCTAGTAACCTCTGGAGGATATGGT  
TGGTCGCTCAGCTATACCCCATAGTAGACCTGGCAGATGAGGCTAGAAACTC  
CCCCACTGGCGACAGTGTTCTAGCCTGCGTGGCTGCCTGCGCACTCTATGAGT  
GCGAAGCCATATATTGACAAGGTGTGAAGAGGCCCGTGTGCTCACCTGAG  
TCCTCCGGCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTCATGAAAT  
CCATCATGTTGCTAGTCGTAATGAGCAATTGCGGGATGGGACCAT

**>HRV67 5'NCR**

TATCCGCAAAGTGCCTACGCAGAGCCTAGTAACTACCTGAAATTACTGGTT  
GGTCGTTCCACCAAACCCATGGTAGACCTGGCAGATGAGGCTAGAAATTCC  
CCACTGGTAACAGTGTCTAGCCTGCCTGGCTGCACACCCCTTGGGTGT  
GAAGCCAAGTAATGGACAGGGTGTGAAGAGGCCGAGTGTGCTACTTGAGTC  
CTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGAGCGCGCAAAC  
CAGCGTGTATCTAGCGTAATGAGCAATTGCGGGACGGGACCAACTACT

**>HRV68 5'NCR**

TATCCGCAAGGCAACTACGCAAAGCCTAGTACCATTTGATGATGTGTGGTT  
GGTCGCTCCACTGTGAACCCGACAGTAGACCTGGCAGATGAGGCTAGAAATT  
CCCCACTGGTAACAGTGTCTAGCCTGCCTGGCTGCCTGCCTACCCCTTGC  
GGTACNAAGCCATACATTGACAAGGTGTGAAGAGGCCCGTGTGCTTGCCTT  
GAGTCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTGTGCAC  
AATCCAGTGCATGGCTAGCGTAACGAGCAATTGCGGGATGGGACCAA

**>HRV71 5'NCR**

TATCCGACATTACTACGCAAAGCCTATTAGCGTTCTGGAAGTTCACTGGCT  
GGTCGTTCCGCTAGACTAACCGCTAGTAGACCTGGCAGATGAGGCTGGAT  
AAACCCCACGGCAGACTGATCCAGCCTGCCTGGCTGCCTGCACACCTGGA  
AACAGGTGTGAAGCCATGAATGGACAGGGTGTGAAGAGGCCCGTGTGCTAA  
GTGTGAGTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCCACAGCTAATAC  
ACACAAACCAGTGTGGATTAGCGTAATGGGTAACTGTGGGACGGAACA

**>HRV73 5'NCR**

TACCCGCAAGATGCCTACGCAAACCTAGTAGCATCTCGAAGATTTGGTT  
GGTCGCTCAGTTGCTACCCAGCAATAGACCTGGCAGATGAGGCTAGAAATA  
CCCCACTGGTACAGTGTCTAGCCTGCCTGGCTGCCTGCACACCCACACGG  
GTGTGAAGCCAAAGATTGGACAAGGTGTGAAGAGTCACGTGTGCTCATCTG  
AGTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCCCGTAGCCATTGCTCGCA  
ATCCAGCGAGTATATGGCGTAATGAGTAATTACGGGATGGGACCGACA

**>HRV74 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAGCACCTTGAAGTCATTGGTT  
GGTCGCTCCGCTGTTCCCCACAGTAGACCTGGCAGATGAGGCTAGAAATACC  
CCACTGGTACAGTGTCTAGCCTGCCTGGCTGCCTGCACACCCCTTGGGTGT  
GAAGCCAAATCATGGACAAGGTGTGAAGAGGCCCGTGTGCTACTTGAGTC  
CTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGAGTCACAAATC  
CAGTGCATTCTAGCGTAATGAGCAATTGCGGGATGGGACCAATT

**>HRV75 5'NCR**

TATCCGCAAGGTGCCTACACAGAGCTTAGTACCGCCTAGAAGGATTGTGGT  
TGGTCGCTCAGTTGCAACCCCAGCAATAGACCTGGCAGATGAGGCTGGACAT  
TCCCCACTGGTGACAGTGGTCCAGCCTGCGTGGCTGCACACCTCTATGA  
GGTGTGAAGCCAGAATTGACAAGGTGCGNAAGAGGCCGCGTGTGCTCACCT  
TGAATCCTCCGGCCCCCTGAATGCGGCTAACCTAAACCCGCAGCCATGGTCC  
ACAATCCAGTGGATGTATGGTCGAATGAGTAATTGTGGATGGCAAT

**>HRV76 5'NCR**

TATCCGAAAACAAC TACGCAAAGCCTAGTACCA CACCTCTAGAGCATGTGGC  
TGGTCGCTCCACTATAAACCCAAATAGTAGACCTGGCAGATGAGGCTAGGAGC  
TCCTCACTGGTAACAGTGCCTAGCCTGCGTGGCTGCACCCCTGACAG  
GTGCGAAGCCAATGTTGACAAGGTGTGAAGAGGCCCGTGTGCTTGTGTTG  
AGTCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTGTGTACA  
ATCCAGTGCATAGCTAGTCGAATGAGCAATTGCGGGATGGGACA

**>HRV77 5'NCR**

TATCCGCAAGGTGCCTACACAAAGCTTAGTAACATTTGAAGAGCATTGGTT  
GGTCGCTCAGCTATTACCCATAGTAGACCTGGCAGATGAGGCTAGAAGTTC  
CCCACTGGCGACAGTGTCTGCCTGCGTGGCTGCCTGCACACTCATGAGT  
GCGAAGCCATATGTTGACAAGGTGTGAAGAGGCCCGTGTGCTCACCTGAG  
TCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTGCATGAAAT  
CCATCATGTAGCTAGTCGAATGAGCAATTGCGGGATGGGACAAG

**>HRV78 5'NCR**

TATCCGCAAGGTGCCTACGGGAAGCCTATT AACACTTTGAAAGAAATTGGC  
TGGTCGCTCAGTTGCGCAATCCCACGCAATAGACCTGGCAGATGGGGCTAGA  
CAAACCCCACCAGCGATGGTGGTCTAGCCCGCGTGGCTGCCTGCACACCCCTT  
TTTGGGGTGTGAAGCCAGAAATTGGACAGGGTGCAGAGGCCTACTGTGCTC  
ACCTTGAGTCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTGTTG  
CACAAGATCCATTGTGTATACAGTCGAATGAGCAATTGCGGGATGGAAC

**>HRV79 5'NCR**

TACCCGCCAACCAACTACGTAATGGCTAGTAACATCATTGATTAGATTGGCG  
TTCGATCAGGTGGTATCCCCCCCACANAGTTGGTCATGAGGCTAGGAATAC  
CCCACGGGTGACCGTGTCTAGCCTGCGTGGCGGCCAACCCAGCATA CGCTG  
GGACGCCAGTTACTGACATGGTGCAGAGACTTGCATGTGCTTGGTTGAGAG  
TCCTCCGGCCCCCTGAATGCGGCTAACCTAACCCGGAGCCTCGCAGCATAA  
TCCAATGTTGTAGAGGTCGTAACGAGTAATTCTGGGATGGGACCGATTGG

**>HRV80 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCTTAGTAACACTTGAAGAATGTGTGGT  
TGGTCGTTCCGCTATTCCCAGTAGACCTGGCAGATGAGGCTAGAAAATCC  
CCACTGGTGACAGTGTCTAGCCTGCCTGGCTGCCTGCACCTTTGAGGT  
GCGAAGCCATTCCCTTGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCTGCAGTAGTCATGCAATC  
CAGCATGTCTCTAGTCGAATGAGTAATTGCGGGATGGGACATTGG

**>HRV81 5'NCR**

TATCCGCAAGATGCCTACGCAAAGCTAGTAATGCTTCGAAGATACTGGTT  
GGTCGCTCAGCTGTGCACCCGACAGTAGACCTGGCAGATGAGGCTAGAAAGTA  
CCCCTCTGGTGACAGAGTTCTAGCCTGCCTGGCTGCCTGCACACCCATTGGG  
TGTGAAGCCAAATATTGGACAAGGTGTGAAGAGAGCCCCGTGTGCTCATCTTGA  
GTCCTCCGGCCCCCTGAATGTGGCTAACCTAACCTGCAGCCAGTCACACAA  
AACCAAGTGTGTAGCTGGTCGAACGAGCAATTGCAGGATGGGACCATT

**>HRV82 5'NCR**

TATCCGCAAGATGCCTACACAAAGCTTAGTACCTCCTTGACGGTATTGTCT  
GGTCGCTCAGGTGTTCCCCAGCACTAGACCTGGCAGATGAGGCTAGAAACT  
CCCCACTGGTGACAGTGTCTAGCCTGCCTGGCTGCCTGCACACCCATTGGG  
TGTGAAGCCAAATACTAGACAAGGTGTGAAGAGAGCCCCGTGTGTTCATCTTGA  
GTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCCGCAGCCATTACTCACA  
ATCCAGTGAGCGGATGGTCGAATGAGCAATTGTGGGATGGGACCGACT

**>HRV83 5'NCR**

TATCCGCCAATCAACTACGTAATGGCTAGTAACACCATGAAGGTAAGTTGAC  
GTTCGATCAGGTGGTAACCCCCACTAGTTGGTCATGAGGCTAGGAATTCCC  
CACGGGTAAACCGTGTCCCTAGCCTGCCTGGCGGCCAACCCAGCATTGCTGGG  
ACGCCAATTACTGACATGGTGTGAAGACTTGCAATGTGCTTGATTGTGACTCC  
TCCGGCCCCCTGAATGCGGCTAACCTAACCCGGAGCCTGCAGCATAATCC  
AATGTTGTGGAGGTCGAATGAGCAATTCTGGGATGGGACCGACTACTG

**>HRV88 5'NCR**

TATCCGCACATTAACTACGCAAAGCTAGTATGCCCTTGATGTATTAAGACT  
GGTCGTTCCCTGCATACCCAGCAGTAGACCTGGCAGATGAAGCTGGACGTT  
CCCACTGGCGACAGTGGCCAGCCTGCCTGGCTGCCTGCTCACCCATTGGGT  
GAGAAGCCTTATTATTGACAAGGTGTGAAGAGAGCCCCGTGTGCTTAATGTGAA  
TCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCGCAGCCGTACTCACAAT  
CCAGTGAAATGACGGTCGAACCGCGAAAGTGTGGGATGGGACCAACTA

**>HRV90 5'NCR**

TATCCGCAGGAGCAACTACGCAAAGCTTAGTACCACTTCAATGGGTATGG  
CTGGTCGCTCCACTATAAACCCAATAGTAGACCTGGCAGATGAGGCTAGAAA  
CTCCCCACTGGTAACAGTGTCTAGCCTGCGTGGCTGCCTGCGTGCCTTTG  
GGCACGAAGCCTACATTGACAAGGTGCGAAGAGCCCCGTGCTGCTT  
GAGTCCTCCGGCCCTGAATGTGGCTAACCTAACCCCTGAGCTAGTGTG  
AATCCAGCACATGGCTAGTCGAATGAGCAATTGCGGGATGGGACCAAC

**>HRV92 5'NCR**

TATCCGCAATCAACTACGTAATGGCTAGTAGCACCTGGATTAAAGTGGCG  
TTCGATCAGGTGGTAACCCCCACTAGTTGGTCGATGAGGCTAGGAATTCCC  
ACGGGTGACCGTGTCCCTAGCCTGCGTGGCGCCAACCCAGCATCCGCTGG  
GCCAATTAAATGACATGGTGTGAAGACCTGCATGTGCTGATTGTGAGTC  
CCGGCCCTGAATGCGGCTAACCTAACCCGGAGCCTGAGCACAATCCA  
GTGTTGTTAAGGTCGAATGAGCAATTCTGGGATGGGACCGACTATGG

**>HRV93 5'NCR**

TAACCGCCAATCAACTACGTAACGGCTAGTATTACCTGTTGCAATCTGGCG  
TTCGATCAGGTGGTCCCCCCTAGTTGGTCGATGAGGCTAGGAGTCCCC  
ACGGGCGACCGTGTCCCTAGCCTGCGTGGCGCCAACCCAGCATTGCTGG  
CAGCCTTTGTAGACATGGTGTGAAGACCTGCATGTGCTGATTGTGAGTC  
TCCGGCCCTGAATGCGGCTAACCTAACCCGGAGCCTGAGCACAATCCC  
CAATGTCCATTGAAGGTCGTAATGAGCAATTCC

**>HRV94 5'NCR**

TATCCGCAAGATGCCTACGCAAAGCCTAGTAGTGCTTGAAAATATTGTCT  
GGTTGCTCAAGTACAACCCCAGTACTAAACCTGGCAGATGAGGCTGGAGCTT  
CCCCACTGGTAACAGTGTCCAGCCTGCGTGGCTGCCTGCACACCCTACGG  
TGTGAAGCCAATATTGGACAAGGTGTGAAGAGCCCCGTGCTCATCTGA  
GTCCTCCGGCCCTGAATGCGGCTAACCTAACCCACAGCCATTGCTCACAA  
TCCAGTGAGTGTATGGTCGTAACGAGCAATTGTGGGATGGGACCGATA

**>HRV95 5'NCR**

TATCCGCAAGATGCCTACGCAAAGCTTAGTAACACACTTGGAGATTATGGCT  
GGTCGTTCCACTATAACCCATAGTAGACCTGGCAGATGAGGCTAGAAATACC  
CCACTGGTGACAGTGTCTAGCCTGCGTGGCTGCCTGCGCACCCATGGGTGC  
GAAGCCATACATTGGACAAGGTGTGAAGAGCCCCGTGCTCATCTTGAGTC  
CTCCGGCCCTGAATGTGGCTAACCTAACCCCGAGCCAATGCACACAATC  
CAGTGTGTTTGGTCGTAATGAGTAATTGTGGGATGGGACCAACTATG

**>HRV96 5'NCR**

TACCCGCAAGATGCCTACGCAACGCCAGTAACATCCTGAATTGTTATGGTT  
GGTCGCTCAATTACAACCCCAGTAATAGACCTGGCAGATGAGGCTAGATATT  
CCCCACTGGCGACAGTGTAGCCTGCGTGGCTGCCTGCACACCCCTGTGG  
GTGTGAAGCCATAATCATGACAGGGTGCAGAGAGCCACGTGTGCTCATCTG  
AGTCCTCCGGCCCTGAATGCGGCTAACCTAACCCCTGCAGCCATTGCCTACA  
AACCAGTGGGTATGTGGTCGAACGAGAAATTGCGGGATGGGACCGAT

**>HRV97 5'NCR**

TATCCGCCAATCAACTACATAACGGCTAGTATCATCATGTTTGATCTGGCG  
TTCGATCAGGTGGTTCCCCACTAGTCTGGTCGATGAGGCTAGGATTCCCC  
ACGGGCGACCGTGTCTAGCCTGCGTGGCGCCAGCCCAGCTTATGCTGGGA  
CGCCTTTAAAGACATGGTGTGAAGACCTGCATGTGCTGATTGTGAGTCCT  
CCGGCCCTGAATGCGGCTAACCTAACCCCTGGAGCCGACAGCATAATCCA  
ATGTTGTTGGGCGTAATGAGCAATTCCGGGATGGGACCGACTATG

**>HRV98 5'NCR**

TATCCGCAAAGTGCCTACGCGAAGCCTAGTAATATCTGAAGAATTATGGTT  
GGTCGCTCCGCCATTACCCATGGTAGACACTGGCAGATGAGGCTAGAAATTCC  
CCACTGGTGACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCCTCACGGGTG  
TGAAGCCATACGTTGACAAGGTGTGAAGAGCCTAGTGTGCTACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCCGTAGCTGGTGACACAAA  
CCAGTGTGTAGCTAGTCGAATGAGCAATTACGGGATGGGACCAATTGG

**>HRV99 5'NCR**

TATCCGCCAGTTAACTGCGAGAAGACTAGTAACCTCCATGTTGTTTAAGCG  
TTCGATCAGGTGGATACCCATTCACTAGTTGGTCGATGAGGCTGGGAATCC  
CCCACAGGTAACTGTGCTCAGCCTGCGTGGCGCCAACCCAGCTTTGCTGG  
GACGCTTACTGACAGACATGGTGTGAAGATCCTATTGCGCTTAACGTGAGTC  
CTCCGGCCCCCTGAATGCGGCTAACCTAACCCCGAGCCTGTGGTGTAAAC  
CAACACTCGCAAGGTCGAACGAGTAATTCTGGGACGGGACCGAT

**>HRV100 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAGTATCTGAAAAGCATGTGGT  
TGGTTGCTCCGCTGTACCCACAGTAAACCTGGCAGATGAGGCTAGAAAGTTC  
CCCACGGTGACAGTGTCTAGCCTGCGTGGCTGCCTGCGCACTCTTGAGTG  
CGAAGCCATATGTTGACAAGGTGTGAAGAGCCCCGTGTGCTACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTCATGCAATC  
CAGCATGTGGCTAGTCGAATGAGCAATTGCGGGATGGGACCAACTATG

**>HANK'S 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAACACCTTGAAGATTATGGTT  
GGTCGTTCCGCTATTCCCCATAGTAGACCTGGCAGATGAGGCTAGAAACCCC  
CCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCGCACCCCTGGGTGC  
GAAGCCATACATTGGACAAGGTGCGAAGAGCCCCGTGCTCACTTGAGTC  
CTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTGCATGTAATCC  
AACATGTTGCTAGTCGAATGAGTAATTGCGGGACGGGACCAACTACT

**>T04-3607 5'NCR**

TATCCGCCAATCAACTACGTAACAGCTAGTAGCATTTGTTGACTGGACG  
TTCGATCAGGTGGTTACCCCCCCACTAGTTGGTCGATGAGGCTGGAAATTC  
CCCACGGGTGACCGTGTCCAGCCTGCGTGGCGGCCAACCCAGCTCATGCTG  
GGACGCCCTTCAATGACATGGTGTGAAGACTCGCATGTGCTTATTGTGAAT  
CCTCCGGCCCCCTGAATGCGGCTAACCTAACCCGGAGCCTGCATCACAAT  
CCAGTGATGTTAGGGTCGAATGAGTAATTCTGGGATGGGACCGACTA

**>T04-3738 5'NCR**

TACCCGCAAGATGCCTACGCAACGCCAGTAACTAGACCTGGCAGATGAGGCTAGATGTT  
GGTCGCTCATTACAACCCAGTAATAGACCTGGCAGATGAGGCTAGATGTT  
CCCCACTGGCGACAGTGTACTAGCCTGCGTGGCTGCCTGCACACCCCTGTGG  
GTGTGAAGCCAATTATGACAAGGTGCGAAGAGGCCACGTGTGCTCATCTG  
AGTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCCCTGCAGCCATTGCTCACA  
AACCAAGTGAGTATGTGGTCGAATGAGAAATTGCGGGACGGGACCGAC

**>T04-3747 5'NCR**

TACCCGCCAATTAACTACGCAACGGCTAGTAATATCATGCTGCTTTAGGGCG  
TTCGATCAGGTGAGTGCACCCCTCACTAGTCTGGTCGATGAGGCTGAGAATTC  
CCCACGGCGACCGTGTCTCAGCCTGCGTGGCGGCCAGCCAGCTTATGCTG  
GGACGCCCTAATTGTGACATGGTGTGAAGACCCACGTGTGCTTAATTGTGAGT  
CCTCCGGCCCCCTGAATGCGGCTAACCTAACCCCTGGAGCCTTGAGACACAAT  
CCAGTGTGGCAAGGTGCGTAATGAGTAATTCCGGGACGGGACCGACTA

**>T04-3933 5'NCR**

TACCCGCGCATCAACTACGCAAAGCCTAGTACCATCTTGATGTATTAAGACT  
GGTCGTTCCCTGCAACCCAGCAGTAGACCTGGCAGATGAGGCTGGACNTAC  
CCCACTGGCGACAGTGGCCAGCCTGCGTGGCTGCCTGCTGCCATATGGG  
CGAGAAGCCTATTATTGACAAGGTGTGAANAGCCGCGTGTGCTTGTGA  
GTCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAACCATTGCCATAA  
TCCAATGGGTTGGTGGTCGAATGCGCAAGTGCAGGGATGGGACCAACTA

**>T04-4310 5'NCR**

TATCCGCAAAGCGCCTACGCAAAGCTTAGTAGCACCTTGAGATTGTTGGTT  
GGTCGTTCCGCCATTCCCCCTGGTAGACCTGGCAGATGAGGCTAGAAATACC  
CCACTGGCGACAGTGTCTAGCCTGCCTGGCTGTGCACACCCCTGTGGGTGT  
GAAGCCAAATAATGGACAAGGTGTGAAGAGCCCCGTGTGCTGCTTGANTC  
CTCCGGCCCCCTGAATGCGGCTAACCTAACCCCTGCAGCTAGACACACAAGC  
CAGTGTGTATCTAGTCGTAATGAGCAATTGCGGGATGGGACCGACTATNGGG  
GGNNTTCCGTGAA

**>BMT303 5'NCR**

TATCCGCACTCCTACTACCGCGACGGCTAGTAGGACCATGTTGACTCTTGGGC  
GTTTCGCTCAGCGTGTATCCCCACGTAGATCGGGTAATGGGGCTACACAAC  
CCCCATCGCGACGATGGTAGCCCGCGTGGTGCCTGCCTAGACCTTTG  
GTCTAGGACGCCAAAGAAGAGACAGGGTGTGAAGACCTTAGTGTGCTAGGA  
GTGAGTCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCGTAGCCATGGTGT  
ACAAGCCAGTACATACGTGGCGTAATGGGCAACTATGGGATGGAACCAA

**>BMT306 5'NCR**

TATCCGCAAAGTGCCTACACAAAGCTTAGTAACATTTGAATGATATATGGTT  
GGTCGCTCCGCTATTCCCCATAGTAGACCTGGCAGATGAGGCTGGAAACTCC  
CCACTGGCGACAGTGTCCAGCCTGCCTGGCTGCCTGCCTAGACCTTCACGAGT  
GCGAAGCCATATATTGACAAGGTGCGAAGAGCCCCGTGTGCTCACTTGAG  
TCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTCATACAAG  
CCAGTATGTAGCTAGTCGTAATGAGCAATTGCGGGATGGGACCCAC

**>T05-2094 5'NCR**

TATCCGCAAGATGCCTACACAGAGCCTAGTAGTACTCTAGAAGAATTCTGGC  
TGGTCGCTCAATTGCAAACCCAGCAATAGACCTGGCAGATGAGGCTGGACGT  
TCCCCACTGGCGACAGTGGTCCAGCCTGCCTGGCTGCCTGCACACTCCTTGG  
AGTGTGAAGCCTTAATTGGACAGGGTGCAGAGAGCCCGTGTGCTCATCTT  
GAGTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCTGCAGCCATTGTTGC  
AACCCAGCAAATATGTGGCGTAATGAGTAATTGCGGGATGGGACCGA

**>T02-0106 5'NCR**

TACCCGCAAGATGCCTACGCAAAGCTTAGTAACACCTCGAAGATACTCGGT  
TGGTCGTCATGTGCAACCCAGCATTAGACCTGGCAGATGAGGCTAGAAAT  
CCCCCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCCTGCACACCCCTAACG  
GGTGTGAAGCCTAGTATTGGACAAGGTGTGAAGAGCCCCGTGTGCTCATCTT  
GAGTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCTGCAGCCATTGCTCAC  
AATCCAGTGAAGTTATGGCGTAATGAGTAATTGCGGGATGGGACCGACT

**>T02-0786 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCTAGTAACATTGAATGATATGGTT  
GGTCGCTCCGCTATTCCCCATAGTAGACCTGGCAGATGAGGCTGGAAACTCC  
CCACTGGCGACAGTGTCCAGCCTGCGTGGCTGCCTGCGCACTCTCACGAGT  
GCGAAGCCATATATTGACAAGGTGCGAAGAGCCCCGTGTGCTCACTTGAG  
TCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTCATAACAAG  
CCAGTATGTAGCTAGTCGAATTGAGCAATTGCGGGATGGGACCAACTAC

**>T02-2397 5'NCR**

TATCCGCCAGTTAACTGCGAAAAGACTAGTAACATCATGCACATTCTAGGT  
GTTCAATCAGGTGAAAACCCCATTCACTAGTTGGTCATGAGGCTGAGAGT  
ACCCCACAGGCAGCTGTCTCAGCCTGCGTGGCGCCAACCCGACTTATGT  
CGGGACGCCTATTAATAGACATGGTGTGAAGATCCTATTGCGCTTAGCTGTG  
AGTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCCGGAGTCTTGTGATGTA  
AGCCAACATTGCAAGGTGTAATGAGTAATTCTGGGATGGGACCGACTA

**>T02-2433 5'NCR**

TATCCACAAAAGTGCCTACGCAAAGCCTAGTAATATCTGAATGATATGGTT  
GGTCGTTCAGCTAAACCCCAGTACAGCTGGCAGATGAGGCTGGAAATTCC  
CCACTGGCGACAGTGTCCAGCCTGCGTGGCTGCCTGCGCACTCTACGAGTG  
CGAAGCCATATATTGACAAGGTGTGAAGAGAGCCCCGTGTGCTCACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTCATAACAATC  
CAGTGTGTAGCTAGTCGAATTGAGCAATTGCGGGATGGGACCAACTAC

**>T02-2476 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAATATCTGAATGATATGGTT  
GGTCGTTCAGCTAAACCCCAGTACAGCTGGCAGATGAGGCTGGAAATTCC  
CCACTGGCGACAGTGTCCAGCCTGCGTGGCTGCCTGCGCACTCTATGAGTG  
CGAAGCCATATATTGACAAGGTGTGAAGAGAGCCCCGTGTGCTCACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTCATAACAATC  
CAGTGTGTGGCTAGTCGAATTGAGCAATTGCGGGATGGGACCAACTAC

**>T02-2616 5'NCR**

TATCCGCAAAGAACGCCTACGCAAACCTAGTAACATTGAATGGTACATGG  
TTGGTCGTTCCGCTAAACCCCAGTACAGCTGGCAGATGAGGCTAGAAGTT  
CCCCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCGTGTGCTCTTATGGG  
CACGAAGCCATTACTTGACAAGGTGTGAAGAGTCCCCTGCTCGTCTGA  
GTCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCCAGTGCACACA  
AACCAGTGTGTAGCTGGTCGAACGAGCAATTGCGGGATGGGACCAACTAC

**>T02-2857 5'NCR**

TATCCGCAAAATGCCTACACAAAGCCTAGTATCACTCTAGAAGATGTGTGGT  
TGGTCGCTCAACCGTGAAACCTGACGGTAGACCTGGCAGATGAGGCTAGAAAT  
ACCCCACCTGGCGACAGTGTCTAGCCTGCGTGGCTGCACACCCCTCACG  
GGTGTGAAGCCATTGACAGGGTGAGAAGAGCCCAGTGTGCTCATTT  
GAGTCCTCCGGCCCCCTGAATGTGGCTAACCTAACCTGCAGCCAATGCACA  
CAATCCAGTGTATGGTCGTAACGAGTAATTGCGGGATGGGACCAACT

**>T03-0037 5'NCR**

TATCCGCAAAGCGCCTACGCAAAGCTTAGTAGCACCTTGAGATTGTTGGTT  
GGTCGTTCCGCCATTCCCGTAGACCTGGCAGATGAGGCTAGAAAGTACC  
CCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCACACCCCTGTGGGTGT  
GAAGCCAAAATAATGGACAAGGTGTGAAGAGGCCCGTGTGCTCGCTTGAGTC  
CTCCGGCCCCCTGAATGCGGCTAACCTAACCTGCAGCTAGAGCACACAAAC  
CAGTGTGTATCTAGTCGTAATGAGCAATTGCGGGACGGGACCGACTACT

**>T03-0053 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAACACCTTGAGATTATGGTT  
GGTCGTTCCGCTATTCCCCATAGTAGACCTGGCAGATGAGGCTAGAAACCCC  
CCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCGCACCCCTGGGTGC  
GAAGCCATACATTGGACAAGGTGCGAAGAGGCCCGTGTGCTCACTTGAGTC  
CTCCGGCCCCCTGAATGTGGCTAACCTAACCTGCAGCTAGTGCATGTAATCC  
AACATGTTGCTAGTCGTAATGAGTAATTGCGGGACGGGACCAACTACT

**>T03-0078 5'NCR**

TATCCGCTATAGTACTTCGAGAAACCTAGTATCACCTTGGATTGTTGATGCG  
TTGCGCTCAGCACACTAACCGTGTGTAGCTTGGGTGATGAGTCTGGACATA  
CCCCACTGGTGACAGTGGTCCAGGCTGCGTTGGCGGCCACTCGTGGTAAA  
ACCATGAGACGCTAGACATGAACAAGGTGTGAAGAGTCTATTGAGCTACTAT  
AGAGTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCATGGAGCAAGTGTCTC  
ACAAGCCAGTGAGTTGCTGCGTAATGCGCAAGTCCGTGGCGGAACCG

**>T03-0599 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAATATCTGAATGATATATGGTT  
GGTCGTTAGCTAAACCCATAGTAGACCTGGCAGATGAGGCTGGAAATTCC  
CCACTGGCGACAGTGTCCAGCCTGCGTGGCTGCCTGCGCACTCTACGAGTG  
CGAAGCCATATATTGACAAGGTGTGAAGAGGCCCGTGTGCTCACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCTGCAGCTAGTGCATACAATC  
CAGTGTGTGGCTAGTCGTAATGAGCAATTGCGGGATGGGACCAACTAC

**>T03-0600 5'NCR**

TATCCAGCAAAGATGCCTACACCATAAGCCAAGCTAATATCTTGAATGATAT  
ATGGTTGGTCGTTCACTAAACCCCCACTATACTGGCAGATAAAGCTGG  
AAATTCCCCCTGGCGGACAGTGTCCACCTGCCTGGCTGCCTGCGCACTCT  
TACGAGTGCTAAACCGTATATTGACAAGGTGTGAAGAGGCCCGTGTGCTCA  
CTTGAGTCCTCCGGCCCCGAATGTGGCTAACCTGTAACCTGCAGCAGGTG  
CATACAATCCACTGTGTGGCTAGTCGAATGAGCAATTGCGGGATGGG

**>T03-0634 5'NCR**

TATCCTGCAAAGTGCCTACGCAAAGCCTAGCTAATATCTTGAATGATATATGG  
TTGGTCGTTCACTAAACCCCATACTATACTGGCAGATGAGGCTGGAAATT  
CCCACTGGCGACAGTGTCCAGCCTGCCTGGCTGCCTGCGCACTCTACGAGT  
GCGAAGCCATATATTGACAAGGTGTGAAGAGGCCCGTGTGCTCACTTGAG  
TCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTCATACAAT  
CCAGTGTGTGGCTAGTCGAATGAGCAATTGCGGGATGGGACCAACT

**>T03-0655 5'NCR**

TACCCGCAAAGATGCCTACGCAAAGCCCAGTAATGCACTGGAAGATTATGGC  
TGGTCGCTCCACTATAACCCATAGTAGACCTGGCAGATGAGGCTAGAAGTAC  
CCCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCCTGCGCACCCCTACGGGT  
GCGAAGCCATACATTGGACAGGGTGTGAAGAGGCCCGTGTGCTCATCTGAG  
TCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCGCAGCCAGAGCATACAA  
TCCAGTGTGTGGCTAGTCGAATGAGTAATTGTGGGATGGGACCAACT

**>T03-1753 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAATATCTTGAATGATATATGGTT  
GGTCGTTCACTAAACCCCATACTAGTAGACCTGGCAGATGAGGCTGGAAATT  
CCACTGGCGACAGTGTCCAGCCTGCCTGGCTGCCTGCGCACTCTACGAGT  
CGAAGCCATATATTGACAAGGTGTGAAGAGGCCCGTGTGCTCACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTGGTGCATACAATC  
CAGTGTGTGGCTAGTCGAATGAGCAATTGCGGGATGGGACCAACTAT

**>T03-1808 5'NCR**

TATCCGAAAATGCCTACACAAAGCCTAGCTATCACTCTAGAAGATGTGTGG  
TTGGTCGCTCACTGTGAACCTGACGGTAGACCTGGCAGATGAGGCTAGAAA  
TACCCCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCACACCCCTCACG  
GGTGTGAAGCCATTCACTGGACAGGGTGTGAAGAGGCCAGTGTGCTCATT  
GAGTCCTCCGGCCCCCTGAATGTGGCTAACCTAACCTGCAGCCAATGCACA  
CAATCCAGTGTGTATTGGTCGAACGAGTAATTGCGGGATGGGACCAAC

**>T03-2119 5'NCR (5/2/06)**

TATCCACACACTGCCTACACAGAGCCTAGTACCACTTTGATGTAATTAGGTT  
GGTCGCTCCCTGCAAACCCAGCAGTAGACCTGGCAGATGAGGCTGGACATT  
CCCACTGGCGACAGTGGTCCAGCCTGCGTGGCTGCCTGCACCCCTATTGGGT  
GAGAAGCCTACTTATTGACAAGGTGTGAAGAGGCCGCGTGTGCTCAGTGTGCT  
TCCTCCGGCCCCTGAATGTGGCTAACCTAACCGCTGCAGCCGCTGCCATAAT  
CCAATGGGTCTACGGTGTAAACGCGTAAGTGCAGGGATGGGACCAACTA

**>T03-2151 5'NCR**

TATCCGCAGGATGCCTACGCAAAGCCTAGTAATTCCCTTGAAAGATATTGGTT  
GGTCGTTCCACTATTCCCCATAGTAGACCTGGCAGATGAGGCTAGAAACTCC  
CCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCACACCCCTTGGGTG  
TGAAGCCAAATATTGGACAAGGTGTGAAGAGGCCGCGTGTGCTCATCCTGAGT  
CCTCCGGCCCCTGAATGTGGCTAACCTAACCGCTGCAGCTAGTGCATGCAATC  
CAGCATGTAGCTAGTCGAATGAGTAATTGCAGGGATGGGACCAACTAT

**>T03-2430 5'NCR**

TATCCGCAAGATGCCTACGCAAAGCTTAGTAGTGCCTTGAAAATATTGTCT  
GGTGCTCAGGTACAACCCAGTACTAAACCTGGCAGATGAGGCTGGAGCTT  
CCCCACTGGTAACAGTGTCCAGCCTGCGTGGCTGCCTGCACACCCCTACGG  
GTGTGAAGCCAAATATTGGACAAGGTGTGAAGAGGCCGCGTGTGCTCATCTG  
AGTCCTCCGGCCCCTGAATGCAGCTAACCTAACCCGCAGCCATTGCTCAC  
AATCCAGTGAGTATATGGTCGTAAACGAGCAATTGTGGGATGGGACCGACT

**>T03-2431 5'NCR**

TATCCGCAAGATGCCTACGCAAAGCTTAGTAGTGCCTTGAAAATATTGTCT  
GGTGCTCAGGTACAACCCAGTACTAAACCTGGCAGATGAGGCTGGAGCT  
TCCCCACTGGTAACAGTGTCCAGCCTGCGTGGCTGCCTGCACACCCCTACGG  
GTGTGAAGCCAAATATTGGACAAGGTGTGAANAGGCCGCGTGTGCTCATCTG  
AGTCCTCCGGCCCCTGAATGCAGCTAACCTAACCCGCAGCCATTGCTCAC  
ATCCAGTGAGTATATGGTCGTAAACGAGCAATTGTGGGATGGGACCGACT

**>T03-2433 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAATATCTGAATGATATATGGTT  
GGTCGTTAGCTAAACCCATAGTAGACCTGGCAGATGAGGCTGGAAATTCC  
CCACTGGCGACAGTGTCCAGCCTGCGTGGCTGCCTGCCTACGAGTG  
CGAAGCCATATATTGACAAGGTGTGAAGAGGCCGCGTGTGCTCACTTGAGT  
CCTCCGGCCCCTGAATGTGGCTAACCTAACCGCTGCAGCTAGTGCATACAATC  
CAGTGTGTGGCTAGTCGTAAACGAGCAATTGCAGGGATGGGACCAACTAC

**>T03-2434 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAATATCTTGAATGATATATGGTT  
GGTCGTTCAGCTAAACCCCATAGTAGACCTGGCAGATGAGGCTGGAAATTCC  
CCACTGGCGACAGTGTCCAGCCTGCGTGGCTGCCTGCGCACTCTACGAGTG  
CGAAGCCATATATTGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCTGCAGCTAGTCATACAATC  
CAGTGTGTGGCTAGTCGAATGAGCAATTGCGGGATGGGACCAACTAC

**>T03-3194 5'NCR**

TATCCGCAAGGGTGAECTACGCAAAGCCTAGTAATACCTGAAGAAACTTATGG  
TTGGTCGCTCCACTAAACCCCATAGTAGACCTGGCAGATGAGGCTAGAAATA  
CCCCACTGGTAACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCCTTGGGT  
GTGAAGCCATATTTGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCTGCAGCTAGTCATGCAATC  
CAGCATGTTGCTAGTCGAACGAGTAATTGCGGGATGGGACCAACTAC

**>T03-3195 5'NCR**

TATCCGCAAGGTGAECTACGCAAAGCCTAGTAATACCTGAAGAAACTTATGGT  
TGGTCGCTCCACTAAACCCCATAGTAGACCTGGCAGATGAGGCTAGAAATAC  
CCCACGGTAACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCCTTGGGTG  
TGAAGCCATATTTGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAGTC  
CTCCGGCCCCCTGAATGTGGCTAACCTAACCTGCAGCTAGTCATGCAATCC  
AGCATGTTGCTAGTCGAACGAGTAATTGCGGGATGGGACCAACTACT

**>T03-3596 5'NCR**

TATCCGCGCAATTACTACGCAAAGCCTAGTAACTTCCAAGAAATTCTTGGT  
TGGCCGCTCCGCTGGTACCCACCAGTAGGCTTGGCAGATGAGGCTGAGTAA  
TCCCCACTGGCGACAGTGAECTACGCTGCGTGGCTGCCTACACACCTGGCAA  
CAGGTGTGAAGCCATAGAAAGGACAGGGTGTGAAGAGCCCCGTGTGCTAATT  
GTGATTCTCCGGCCCCCTGAATGCGGCTAACCTAACCCCCACATCCAATGCGC  
ATAAACCAATGCGTAGTTGGCTGAATGGCAACTGTGGGACGGAACCGA

**>T03-4111 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAATATCTTGAATGATATATGGTT  
GGTCGTTCAGCTAAACCCCATAGTAGACCTGGCAGATGAGGCTGGAAATTCC  
CCACTGGCGACAGTGTCCAGCCTGCGTGGCTGCCTGCGCACTCTACGAGTG  
CGAAGCCATATATTGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCTGCAGCTAGTCATACAATC  
CAGTGTGTGGCTAGTCGAATGAGCAATTGCGGGATGGGACCAACTAC

**>T03-4112 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAATATCTTGAATGATATATGGTT  
GGTCGTTCAGCTAAACCCCATAGTAGACCTGGCAGATGAGGCTGGAAATTCC  
CCACTGGCGACAGTGTCCAGCCTGCGTGGCTGCCTGCGCACTCTACGAGTG  
CGAAGCCATATAATTGACAAGGTGTGAAGAGCCCCGTGCTCACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTCATAACAATC  
CAGTGTGTGGCTAGTCGAATGAGCAATTGCGGGATGGGACCAACTAT

**>T03-4196 5'NCR**

TATCCGCAAAGTGCCTACACAGAGCTTAGTAGGATTCTGAAAGATCTTGGTT  
GGTCGCTCAACTGCATAACCCAGCAGTAGACCTTGCAGATGAGGCTGGACATT  
CCCCACTGGTAACAGTGGCCAGCCTGCGTGGCTGCCTGCACACCTCTTATGA  
GGTGTGAAGCCAAGGATTGGACAGGGTGTGAAGAGGCCCGTGTGCTCACTTT  
GAGTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCCCTGCAGCCATGGCTCA  
TAAACCAATGAGTTATGGTCGAATGAGTAATTGCGGGATGGGACCGA

**>T03-4311 5'NCR**

TATCCGCAAGATGCCTACGCAAAGCCTAGTAATGCCTTGAAGATATTGTCT  
GGTGCTCAGGTACAACCCAGTACTAAACCTGGCAGATGAGGCTGGAGTCT  
CCCCACTGGTAACAGTGTCCAGCCTGCGTGGCTGCCTGCACACCCCTCACGG  
GTGTGAAGCCAATATTGGACAAGGTGTGAAGAGGCCCGTGTGCTCATCTG  
AGTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCCACAGCCNTGCTCACA  
ACCCAGTGAGTTATGGTCGAATGAGTAATTGTGGGATGGGACCGACT

**>T03-4474 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCCTAGTAATATCTTGAATGATATATGGTT  
GGTCGTTCAGCTAAACCCCATAGTAGACCTGGCAGATGAGGCTGGAAATTCC  
CCACTGGCGACAGTGTCCAGCCTGCGTGGCTGCCTGCGCACTCTACGAGT  
GCGAAGCCATATAATTGACAAGGTGTGAAGAGGCCCGTGTGCTCACTTGAG  
TCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTCATAACAAT  
CCAGTGTGTGGCTAGTCGAATGAGCAATTGCGGGATGGGACCAACTA

**>T03-4481 5'NCR**

TATCCGCAAGATGCCTACACAAAGCTTAGTACCTCCTTGATGGTATTGTCT  
GGTCGCTCAGGTGTTCCCCAACACTAGACCTGGCAGATGAGGCTAGAAACT  
CCCCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCCTTCGGG  
TGTGAAGCCAATACTGGACAAGGTGTGAAGAGGCCCGTGTGCTCATCTG  
GTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCCCGCAGCCATTACTCACA  
ATCCAGTGAGCAGATGGTCGAATGAGCAATTGTGGGATGGGACCGACT

**>T04-3552A 5'NCR**

TATCCGAAAACAAC TACGCAAAGCCTAGTATCATCTCAAAGATATGTGGT  
TGGTCGCTCCGCTATAAACCAATAGCAGACCTGGCAGATGAGGCTAGAAAT  
CCCCCACTGGCGACAGTGTCTAGCCTGCCTGCCTACACG  
GGTACGAAGCCATATATTGACAAGGTGTGAAGAGCCCCGTGTGCTTGTGCA  
AGTCCTCCGGCCCCCTGAATGTGGCTAACCTAACCTGCAGCTGGTGTGCA  
ATCCAGTACATGCCAGTCGAATGAGCAATTGCGGGATGGGACCAAC

**>T04-3552B 5'NCR**

TATCCGAAAACAAC TACGCAAAGCCTAGTATCATCTCAAAGATATGTGGT  
TGGTCGCTCCGCTATAAACCAATAGCAGACCTGGCAGATGAGGCTAGAAAT  
CCCCCACTGGCGACAGTGTCTAGCCTGCCTGCCTACACG  
GGTACGAAGCCATATATTGACAAGGTGTGAAGAGCCCCGTGTGCTTGTGCA  
AGTCCTCCGGCCCCCTGAATGTGGCTAACCTAACCTGCAGCTGGTGTGCA  
ATCCAGTACATGCCAGTCGAATGAGCAATTGCGGGATGGGACCAAC

**>T04-0424 5'NCR**

TATCCGAAAAGTGCCTACACAGAGCCTAGTAGGATTCTGAAAGATCTTGGTT  
GGTCGCTCAGCTGCATAACCCAGCAGTAGACCTTGAGATGAGGCTGGACATT  
CCCCACTGGTAACAGTGGTCCAGCCTGCCTGGCTGCCTGCACACCTCTACGA  
GGTGTGAAGCCAAGGATTGGACAGGGTGCAGAGAGCCCGTGTGCTCACTTT  
GAGTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCTGCAGCCATGGCTCA  
TAAGCCAATGAGTTATGGTCGAATGAGCAATTGTGGGATGGGACCGA

**>T04-0714 5'NCR**

TATCCGCAATGTGCCTACACAAAGCCTAGTACCATCTGAATGATATATGGTT  
GGTCGCTCCGCCATTCCCCATGGTAGACCTGGCAGATGAGGCTAGAAGCTCC  
CCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCCTGCCTGCACACTCTGAGTGC  
GAAGCCGTATATTGACAAGGTGTGAAGAGCCCCGTGTGCTCACATTGAGTC  
CTCCGGCCCCCTGAATGTGGCTAACCTAACCTGCAGCTAGTGCACACAAAC  
CAGTGTGTAGCTAGTCGAATGGCAACTGCGGGATGGGACCAACTACT

**>T04-0946 5'NCR**

TATCCGCAAGATGCCTACGCAAAGCCTAGTAGCGCATTGAAAGATACTTGGT  
TGGTCGCTCAGCTGTTAACCGACAGTAGACCTGGCAGATGAGGCTAGAGAT  
TCCCTCCGGCGACGGAGTTCTAGCCTGCCTGGCTGCACACCCGGTGGG  
TGTGAAGCCAAATATTGGACAAGGTGTGAAGAGCCCGTGTGCTCATCTGA  
GTCCTCCGGCCCCCTGAATGTGGCTAACCTAACCTGCAGCCAGTGCACACA  
GTCCAGTGTGTAGCTGGTCGAATGAGTAATTGCGGGATGGGACCAACTA

**>T04-0964 5'NCR**

TATCCGCAAGATGCCTACACAGAGCCTAGTAGTACTCTAGAAGAATTCTGGC  
TGGTCGCTCAATTGCAAACCCAGCAATAGACCTGGCAGATGAGGCTGGACGT  
TCCCCACTGGCGACAGTGGTCCAGCCTGCGTGGCTGCCTGCACACTCCTTGG  
AGTGTGAAGCCTTAATTGGACAGGGTGCAGAGGCCCGTGTGCTCATCTT  
GAGTCCTCCGGCCCTGAATGCGGCTAACCTAACCTGCAGCCATTGTTGC  
AACCCAGCAAATATGTGGTCGAATGAGTAATTGCGGGATGGGACCGAC

**>T04-1004 5'NCR**

TATCCGCAAGATGCCTACGCAAAGCCTAGTATCACCTTGATTCTATTGGTT  
GGTCGCTCAGCTACAAACCCAGTAGTAGACCTGGCAGATGAGGCTAGAAATA  
CCCCACTGGTGACAGTGGTCTAGCCTGCGTGGCTGCCTGCACACCCATGGGT  
GTGAAGCCAATTAGTTGACAGGGTGTGAAGAGCCCCGTGTGCTCATCTTGAT  
TCCTCCGGCCCTGAATGTGGCTAACCTAACCTGCAGCCAATGTACACAAT  
CCAGTGTATTATTGGTCGAATGAGTAATTGCGGGATGGGACCAACTA

**>T04-1325 5'NCR**

TACCCGCAAGGTGCCTACACAGAGCCTAGTATCATCTTAGAAGAATTGTGGT  
TGGTCGCTCAGTTGCAAACCCAGCAATAGACCTGGCAGATGAGGCTGGACAT  
TCCCCACTGGTGACAGTGGTCCAGCCTGCGTGGCTGCCTGCACACCTCTATGA  
GGTGTGAAGCCAGAATTGACAAGGTGTGAAGAGGCCCGTGTGCTCACCTT  
GAGTCCTCCGGCCCTGAATGCGGCTAACCTAACCCCGCAGCCATGGTCCA  
CAAACCAGTGGATGTGGTCGAATGAGTAATTGTGGGATGGGACCGAC

**>T04-1411 5'NCR**

TATCCGCAAAGTGCCACGCAAAGCCTAGTAGCACTTAGATTGTTATGGTT  
GGTCGCTCAGCNTATTCCCCCTAGTAGACCTGGCAGATGAGGCTAGAAATA  
CCCCACTGGTAACAGTGGTCTAGCCTGCGTGGCTGCCTGCGCACCCCTTCGGG  
TGCAGGCCATATACATGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGA  
GTCCTCCGGCTCCTGAATGTGGCTAACCTAACCTGCAGCCAGTGCACATA  
AGCCAATGTGTATCTGGTCGAATGAGTAATTGCGGGATGGGACCAACT

**>T04-2387 5'NCR**

TACCCGCAAGATGCCTACGCAAAGCTTAGTATCACCTTGATTTTATTGGTT  
GGTCGTTCAGCTACAAACCCAGTAGTAGACCTGGCAGATGAGGCTAGAAACA  
CCCCACTGGTAACAGTGGTCTAGCCTGCGTGGCTGCCTGCACACCCATGGGT  
GTGAAGCCGACTAATTGACAAGGTGTGAAGAGCCCCGTGTGCTCATCTTGAT  
TCCTCCGGCCCTGAATGTGGCTAACCTAACCTGCAGCCAATGTACACAAT  
CCAGTGTGCTGTGGTCGAATGAGTAATTGCGGGATGGGACCAACTA

**>T04-3190 5'NCR**

TATCCGCCAATTAAC TACGCAACGGCTAGTAACATCTTGTATTCTTAGGGCG  
TTCGATCAGGTGAGTATA CCCCTCACTAGTCTGGTCGATGAGGCTGAGAAC  
CCCACGGGCGACC GTCTCAGCCTGCCTGGCGGCCAGCCCAGCTTATGCTG  
GGACGCCTTAATTGTGACATGGGTGAAGACCCACGTGTGCTTAATTGTGAGT  
CCTCCGGCCCCCTGAATGCGGCTAACCTAAACCCCTGGAGCCTTGAGACACA  
CCAGTGTGGCAAGGTGTAATGAGCAATTCCGGACGGGACCGACTA

**>T04-3247 5'NCR**

TACCCGCGCATCAACTACGCAAAGCCTAGTACCATCTTGATGTATTAAGACT  
GGTCGTTCCCTGCAACCCCAGCAGTAGACCTGGCAGATGAGGCTGGACGTAC  
CCCACTGGCGACAGTGGTCCAGCCTGCCTGGCTGCCTGCACACCCATATGGG  
CGAGAACCTTATTATTGACAAGGTGTGAAGAGGCCGCGTGTGCTTGTGA  
GTCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCCATTGCCATAA  
TCCAATGGGTTGGTGGTCGTAATGCGCAAGTGCAGGGATGGGACCAACTA

**>T04-3641 5'NCR**

TATCCGCAAAGT GACTACGCAAAGCCCAGTAATATCTTGAAGAACCTTATGGC  
TGGTCGTTCCGCTAAACCCCATA GTAGACCTGGCAGATGAGGCTAGAAATAC  
CCCACTGGAGACAGTGTCTAGCCTGCCTGGCTGCCTGCACACCCATGGGT  
GTGAAGCCATATTTGACAAGGTGTGAAGAGGCCCGTGTGCTCACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTACATGCAATC  
CAGCATGTTGCTAGTCGTAACGAGCAATTGCAGGGATGGGACCAACTACT

**>T04-3642 5'NCR**

TATCCGCAAAGT GACTACGCAAAGCCCAGTAATATCTTGAAGAACCTTATGG  
CTGGTCGTTCCGCTAAACCCCATA GTAGACCTGGCAGATGAGGCTAGAAATAC  
CCCACTGGAGACAGTGTCTAGCCTGCCTGGCTGCCTGCACACCCATGGGT  
GTGAAGCCATATTTGACAAGGTGTGAAGAGGCCCGTGTGCTCACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTACATGCAATC  
CAGCATGTTGCTAGTCGTAACGAGCAATTGCAGGGATGGGACCAACTAC

**>T04-3643 5'NCR**

TATCCGCAAAGT GACTACGCAAAGCCCAGTAATATCTTGAAGAACCTTATGGC  
TGGTCGTTCCGCTAAACCCCATA GTAGACCTGGCAGATGAGGCTAGAAATAC  
CCCACTGGAGACAGTGTCTAGCCTGCCTGGCTGCCTGCACACCCATGGGT  
GTGAAGCCATATTTGACAAGGTGTGAAGAGGCCCGTGTGCTCACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTACATGCAATC  
CAGCATGTTGCTAGTCGTAACGAGCAATTGCAGGGATGGGACCAACTACT

**>T04-3644 5'NCR**

TATCCGCCAAAGGTGGACCTACGCAAAGCCCAGNTAATATCTTCCAAGAAC  
TTATGGCCTGGTCGTTCCGCCTAAACCCCATAGTAGACCTGGCAGAATGAG  
GCTAGAAATACCCCACTGGAGACAGTGTCTAGCCTCGGTGGCTGCCTGCAC  
ACCCTATGGGTGTGAAGCCATATTTGACAAGGTGTGAAGAGCCCCGTGTG  
CTCACTTGAGTCCGGCCCTGAATGTGGCTAACCTAACCTGCAGCTAG  
TACATGCAATCCAGCANGTTGCTAGTCGTAACGAGCAATTGCGGGATGGG

**>T04-3645 5'NCR**

TATCCGCCAAAGTGACTACGCAAAGCCCAGTAATATCTTGAAGAACTTATGGC  
TGGTCGTTCCGCTAAACCCCATAGTAGACCTGGCAGATGAGGCTAGAAATA  
CCCCACTGGAGACAGTGTCTAGCCTCGGTGGCTGCCTGCACACCCATGGGT  
GTGAAGCCATATTTGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAGT  
CCTCCGGCCCTGAATGTGGCTAACCTAACCTGCAGCTAGTACATGCAATC  
CAGCATGTTGCTAGTCGTAACGAGCAATTGCGGGATGGGACCAACTAC

**>T04-3903 5'NCR**

TATCCGCCAGTTAACTACGCAACAGCTAGTAACATCTTGTGTTCTAGGGCG  
TTCGATCAGGTGAGCTTACCCCTCACTAGTCTGGTCATGAGGCTGAGAAA  
CCCCCACGGGCGACCGTGTCTCAGCCTCGGTGGCCAGCCCAGCATATGC  
TGGGACGCCCTAACGTATGACATGGTGTGAAGACTCGCGTGTGCTTAGCTGTG  
AGTCCTCCGGCCCTGAATGCGGCTAACCTAACCCGGAGCCTTGAGGTACA  
ATCCAGTACCCGTGAGGTCGTAATGAGTAATTCTGGGACGGGACCGACTA

**>T04-3906 5'NCR**

TATCCGCCAAAGGTGACTACGCAAAGCCTAGTAATACCTTGAAGAACTTATGGT  
TGGTCGCTCCACTAAACCCCATAGTAGACCTGGCAGATGAGGCTAGAAATAC  
CCCACTGGTAACAGTGTCTAGCCTCGGTGGCTGCCTGCACACCCCTTGGGTG  
TGAAGCCATATTTGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAGTC  
CTCCGGCCCTGAATGTGGCTAACCTAACCTGCAGCTAGTGCATGCAATCC  
AGCATGTTGCTAGTCGTAACGAGCAATTGCGGGATGGGACCAACTACT

**>T04-3934 5'NCR**

TATCCGCCAAAGGTGACTACGCAAAGCCTAGTAATACCTTGAAGAACTTATGGT  
TGGTCGCTCCACTAAACCCCATAGTAGACCTGGCAGATGAGGCTAGAAATAC  
CCCACTGGTAACAGTGTCTAGCCTCGGTGGCTGCCTGCACACCCCTTGGGTG  
TGAAGCCATATTTGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAGTC  
CTCCGGCCCTGAATGTGGCTAACCTAACCTGCAGCTAGTGCATGCAATCC  
AGCATGTTGCTAGTCGTAACGAGCAATTGCGGGATGGGACCAACTACT

**>T04-3939 5'NCR**

TATCCGCAAGGGTGAECTACGCAAAGCCTAGTAATACCTGAAGAACTTATGG  
TTGGTCGCTCCACTAAACCCCATACTAGTAGACCTGGCAGATGAGGCTAGAAATA  
CCCCACTGGTAACAGTGTCTAGCCTGCCTGGCTGCACACCCCTTGGGT  
GTGAAGCCATATTTGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAGT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTCATGCAATC  
CAGCATGTTGCTAGTCGTAACGAGCAATTGCGGGATGGGACCAACTAC

**>T04-4103 5'NCR**

TATCCGCAAAGCGCCTACGCAAAGCTTAGTACGCATCTCGAAATTGTCGGTT  
GGTCGTTCCGCCATTCCCCCTGGTAGACCTGGCAGATGAGGCTAGAAATAC  
CCCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCACACCCATGGGT  
GTGAAGCCAAACAATGGACAAGGTGTGAAGAGAGCCCCGTGTGCTCGCTTGAG  
TCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGAGCACGCAA  
ACCAGCGTGTCTAGTCGTAATGAGCAATTGCGGGATGGGACCAACTA

**>T05-0000 5'NCR**

TATCCGAAAATGCCTACACAAAGCCTAGTATCATCTTGAAGGCACAGAGT  
TGGTCGTTCCGCTATTCCCCATACTAGTAGACCTGGCAGATGAGGCTAGAAAACC  
CCCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCCTGCAGCTGAGGC  
ACGAAGCCCTGTGTTGACAAGGTGTGAAGAGAGCCCCGTGTGCTCATTGATT  
CCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGAGCACGCAA  
CCAGTGTGTATCTAGTCGTAATGAGCAATTGCGGGACGGGACCAACT

**>T05-1034 5'NCR**

TATCCCCGCATTGCCTACACAGAGCCTAGTACCGCCTTGATGTATTTAGACT  
GGTCGTTCCCTGCAAACCCAGCAGTAGACCTGGCAGATGAGGCTGGACGTT  
CCCACTGGCGACAGTGGCCAGCCTGCCTGGCTGCCTGCCACCCATTGGGT  
GGGAAGCCTAATTATTGACATGGTGTGAAGAGGCCGCGTGTGCTCAATGTGTC  
TCCTCCGGCCCCCTGAATGTGGCTAACCTAACCCCTGCAGCCGCTGTCCACAAG  
CCAGTGGATATACGGTCGTAATGCGTAAGTGCAGGGATGGGACCAACTA

**>T05-1161 5'NCR**

TATCCGCAAGATGCCTACGCAAAGCTTAGTACGCATCTTGA AAAAATCTGGTT  
GGTCGCTCATGTGCAACCCAGCATTAGACCTGGCAGATGAGGCTAGAAATT  
CCCCACTGGTGACAGTGTCTAGCCTGCCTGGCTGCCTGCACACCCCTAACGG  
GTGTGAAGCCTAGTATTGGACAAGGTGTGAAGAGAGCCCCGTGTGCTCATCTG  
AGTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCCCTGCAGCCATTGCTCACA  
ATCCAGTGAAGTTATGGTCGTAATGAGCAATTGCGGGATGGGACCGACT

**>T05-1169 5'NCR**

TACCCGACCAACTACTTCGAGAAGCTTAGTACCAACCATGAACGAGGCAGAGT  
GTTTCGTTTCAGCACAACCCCAGTGTAGATCAGGCTGATGAGTCAGTCACCGAAC  
CCCATGGGCGACCATGGCAGTGGCTGCCGGCCTGCCATGGAGAAAT  
CCATGGGACGCTCTAATTCTGACATGGTGTGAAGAGCCTATTGAGCTAGCTG  
GTAGTCCTCCGGCCCTGAATGCGGCTAACCTAACTGCGGAGCACATGCTC  
ACAAACCAGTGGGTGGTGTGCGTAATGGCAACTCTGCAGCGGAACCG

**>T05-1262 5'NCR**

TATCCGCAAAGTGCCTACGCAAAGCTTAGTAACACTTGGAAAGGTCTATGGTT  
GGTCGCTCAGCTAAACCCCATACTAGTAGACCTGGCAGATGAGGCTAGAAACTCC  
CCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCACACCCCTACGGGT  
GTGAAGCCATATACTCGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAG  
TCCTCCGGCCCTGAATGTGGCTAACCTAACCCCGCAGCTAGTGCATACAA  
ACCAAGTATGTGGCTAGTCGTAATGAGCAATTGTGGATGGGACCAACTAC

**>T05-1430 5'NCR**

TATCCGCAAGATGCCTACGCAAAGCCTAGTAGCATCTTGAAAATACTGGTT  
GGTCGCTCATGTGCTACCCAGCATTAGACCTGGCAGATGAGGCTAGAAATT  
CCCCACTGGCGACAGTGTCTAGCCTGCCTGGCTGCCTGCACACCCCTAACGG  
GTGTGAAGCCTAGTATTGGACAAGGTGTGAAGAGCCCCGTGTGCTCATCTG  
AGTCCTCCGGCCCTGAATGCGGCTAACCTAACCCCTGCAGCCATTGCTCACA  
ATCCAGTGAGTCTATGGTCGTAATGAGCAATTGCGGGATGGGACCGACT

**>T05-1688 5'NCR**

TATCCGCAAAGTGAECTACGCAAAGCCTAGTAATATCTTGAAAGAACTTATGGC  
GGTCGCTCCGCTAAACCCCATACTAGTAGACCTGGCAGATGAGGCTAGAAATAC  
CCCACTGGAGACAGTGTCTAGCCTGCCTGGCTGCACACCCCTATGGGT  
GTGAAGCCATATTGGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAGT  
CCTCCGGCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTGCATGCAATC  
CAGCATGTTGCTAGTCGTAACGAGCAATTGCGGGATGGGACCAACTACT

**>T05-1711 5'NCR**

TATCCCCGCATTGCCTACACAGAGCCTAGTATCACTTTGATATATTTAGACT  
GGTCGCTCCCTGCAAACCCAGCAGTAGACCTGGCAGATGAGGCTGGACGCTC  
CCCACTGGCGACAGTGGCCAGCCTGCCTGGCTGCCTGCCACCCATTGGGT  
GGGAAGCCTAATTATTGACAAGGTGTGAAGAGCCCGTGTGCTCAATGTGTT  
TCCTCCGGCCCTGAATGTGGCTAACCTAACCCCGCAGCCGCTGTCCACAAA  
CCAGTGGATATACGGTCGTAATGCGCAAGTGTGGATGGGACCAACTA

**>T05-1738 5'NCR**

TATCCGCAAAGCAACTACGCAAAGCTTAGTATCACCTCTAGAGCATGTGAC  
TGGTCGCTCCACTATAAACCAATAGTAGACCTGGCAGATGAGGCTAGGAGT  
TCCTCACTGGTAACAGTGCCTAGCCTGCGTGGCTGCCTGCACACCCAAACAG  
GTGTGAAGCCATATGTTGACAAGGTGTGAAGAGCCCCGTGTGCTGCTTGA  
GTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCTGCAGCTAGTGCACACA  
ATCCAGTGCCTGGCTAGTCGAATGAGCAATTGCGGGACGGGACCAACT

**>T05-2142 5'NCR**

TATCCGCAAGATGCCTACGCAAAGCCTAGTAGCGCTCTGAAATTGGTTGGTT  
GGTCGCTCAGGTGCAAACCCAGCACTAGACCTGGCAGATGAGGCTAGAAAAT  
CCCCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCATTGGG  
TGTGAAGCCAACACAACGGACAGGGTGTGAAGAGCCCCGTGTGCTCATCTTG  
TTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCTGCAGCCATTGCTCACAA  
TCCAGTGAGTTGGTGGTCGAATGAGCAATTGCGGGATGGGACCGACT

**>T05-2181 5'NCR**

TATCCGCAAGATGCCTACGCAAAGCCTAGTAGCGCTCTGAAATTGGTTGGTT  
GGTCGCTCAGGTGCAAACCCAGCACTAGACCTGGCAGATGAGGCTAGAAAAT  
CCCCACTGGTGACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCATTGG  
GTGTGAAGCCAACACAACGGACAGGGTGTGAAGAGCCCCGTGTGCTCATCTTG  
ATTCCCTCCGGCCCCCTGAATGCGGCTAACCTAACCTGCAGCCATTGCTCACAA  
ATCCAGTGAGTTGGTGGTCGAATGAGCAATTGCGGGATGGGACCGAC

**>T05-AAAA 5'NCR**

TATCCGCAAGGTGCCTACACAGAACTTAGTACCATTCTGGAAAATTCTGGCT  
GGTCGTTCAATTACTACCCCCAGTAATAGACCTGGCAGATGAGGCTAGAAGTT  
CCCCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCACACCCATTGGG  
GTGTGAAGCCTAGAATTGGACAGGGTGTGAAGAGTCGCGTGTGCTCATCTTG  
AGTCCTCCGGCCCCCTGAATGCGGCTAACCTAACCTGCAGCCATTGCCAC  
AATCCAGTGGGTCTATGGTCGAATGAGCAATTGCGGGATGGGACCGAC

**>V06T01974 5'NCR**

TATCCGCGCAATTACTACACAAAGCTTAGTAACCTCCAAGAAATTCTTGGT  
TGGCCGCTCCGCTGGTACCCCACCAAGTAGGCTTGGCAGATGAGGCTGAGTAA  
TCCCCACTGGCGACAGTGAECTAGCCTGCGTGGCTGCCTACACACCTGGCAA  
CAGGTGTGAAGCCATAGAAAGGACAGGGTGTGAAGAGCCCCGTGTGCTAATT  
GTGATTCTCCGGCCCCCTGAATGCGGCTAACCTAACCCACATCCAATGCGC  
ATAAACCAATGCGTAGTTGGTCGAATGGGCAACTGTGGGACGGAACC

**>V06T02157 5'NCR**

TACCCGCAGGCATGCCTACGCAAAGCCCAGTAATACTGGAAAGATTATGG  
CTGGTCGCTCCACTATAACCCCATAGTAGACCTGGCAGATGAGGCTAGAAGTA  
CCCCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCCTGCGCACCCCTACGGGT  
GCGAAGCCATACATTGGACAGGGTGTGAAGAGCCCCGTGTGCTCATCTTGAG  
TCCTCCGGCCCCTGAATGTGGCTAACCTAACCCGCAGCCAGAGCATACAA  
TCCAGTATGTTCTGGTCGAATGAGTAATTGTGGATGGGACCAACTAC

**>V06T032267 5'NCR**

TATCCGCCAGTTAACTACGTAAACGGCTAGTAACATCTTGTGCTTAGGGTG  
TTCGATCAGGTGAAGAAAAACCCCTTCACTAGTCTGGTCGATGAGGCTGAG  
AAGTCCCCACGGCGACCGTGTCTCAGCCTGCGTGGCGGCCAGCCCAGCATA  
TGCTGGGACGCCTTAAGTATGACATGGTGTGAAGACCCGATGTGCTTAAC  
GTGAGTCCTCCGGCCCCTGAATGCGGCTAACCTAACCCCTGGAGGCCTGGAG  
ACAAGCCAGTGCTTACAAGGTGTAATGAGCAATTCCGGGACGGGACCG

**>V06T04424 5'NCR**

TATCCGCAAGGTGACTACGCAAAGCCTAGTAATACTTGAAGAACTTATGGT  
TGGTCGCTCCACTAAACCCATAGTAGACCTGGCAGATGAGGCTAGAAATAC  
CCCACTGTAACAGTGTCTAGCCTGCGTGGCTGCACACCCTCGGGTG  
TGAAGCCATATTTGACAAGGTGTGAAGAGCCCCGTGTGCTCACTTGAGTC  
CTCCGGCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGTGCATGCAATCC  
AGCATGTTGCTAGTCGTAACGAGCAATTGCGGGATGGGACCAACTATT

**>V06T01895 5'NCR**

TATCCGCCAGTTAACTACGTAAACGGCTAGTAACATCTTGTGCTTAGGGTG  
TTCGATCAGGTGAAGAAAAACCCCTTCACTAGTCTGGTCGATGAGGCTGTA  
GCAAGTCCGCCACGGCGACCGTGTCTCAGCCTGCGTGGCGGCCAGCCCAGC  
ATATGCTGGCACGCCTTAAGTACGACATGGTGTGAAGACCCGATGTGCTT  
AACTGTGAGTCCTCCGGCCCCTGTAATGCGGCTAACCTAACCCCTGGAGCCTT  
GGAGCACAAAGCCAGTGCTTACAAGGTGTAATGAGCAATTCCGGGACGG

**>V06T01884 5'NCR**

TATCCGCAAAGGCCCTACGCAAAGCCTAGTAACTATCTGGAAATTGCTTGGTT  
GGTCGCTCCGCCATACCCCATGGTAGACCTGGCAGATGAGGCTAGAAACTCC  
CCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCACACCCTTTGGGTG  
TGAAGCCAAGTAACGGACAGGGTGTGAAGAGCCCCGTGTGCTCGCTTGAGT  
CCTCCGGCCCCTGAATGTGGCTAACCTAACCCCTGCAGCTAGGGCACACAAC  
CCAGTGTGTATCTAGTCGTAATGAGCAATTGCGGGATGGGACCAATTGT

**>V05T05509 5'NCR**

TACCCCGCGAAAGTCCTACCGAAGCCTAGTAACATCTGAAGAATTATGG  
TTGGTCGCTCCACTATTCCCCATAGTAGACCTGGCAGATGAGGCTAGAAATT  
CCCACTGGCGACAGTGTCTAGCCTGCGTGGCTGCACACCCCTACGGGT  
GTGAAGCCATATATTGACAAGGTGTGAAGAGCCTAGTGTGCTCACTTGAG  
TCCTCCGGCCCTGAATGTGGCTAACCTAAACCCGTAGCTAGTCATAACAT  
CCAGTGTGTGGCTAGTCGAACGAGCAATTACGGGATGGGACCAACTA

**>V06T01482 5'NCR**

TATCCGCACATTAACACTACACAAAGCCTAGTATCACCTTGATGTATTAAGACT  
GGTCGCTCCCTGCATACCCAGCAGTAGACCTGGCAGATGAGGCTGGACATTC  
CCCACTGGTGACAGTGGTCCAGCCTGCGTGGCTGCCTGCTCACCCATTGGGT  
GAGAAGCCTTATTATTGACAAGGTGTGAAGAGCCCCGTGTGCTTAATGTGAA  
TCCTCCGGCCCTGAATGTGGCTAACCTAACCCCTGCAGCCGTTACTCACAAT  
CCAGTGAATGGCGGTGTAATGCGAAAGTGCAGGGATGGGACCAACTA


**>V06T0477 5'NCR**

TATCCGCACATTAACACTACGCAAAGCCTAGCATCGCCTTGATGTATTAAGACT  
GGTCTGTGCCCTGCATACCCAGCAGTAGAGGTGGCAGATGAAGCTGGACGT  
TCCCCAGCTGGCGACAGTGGTCCAGCCTGTCGGTGGGCTGCGCTGCTCAGCG  
CCACTATTGGGTGAGAAGCTCTTATTATTGACAAGGTGTGAAGAGTCCCCGT  
GTGCTTAATGTGAATCCTCCGGCCCTGAATGTGGCTAACCTAACCCCGAG  
CACGTTACAACGCACTTCCGTTGCCAACGAGTACATT


APPENDIX G. LIST OF ACCESSION NUMBERS FOR THE 5'NON-CODING  
REGION SEQUENCES OBTAINED FROM GENBANK

AF108179  
D00239  
X02316  
AF542425  
AF108185  
K02121  
L24917  
AF542419  
AF108180  
AF108181  
AF108182  
AY751783  
AF542422  
AF542423  
AF108183  
AF542424  
AF108184  
AF542426  
AF542427  
AF108186  
AF542429  
AF542430  
AF542431  
AY062273  
A10937  
AF542432


## APPENDIX H. EQUIPMENT USED FOR MICROARRAY



**Figure 7.** Microarrayer used for spotting PCR products on aminosilane glass slides



**Figure 8.** Hybridization chamber with microarray



**Figure 9.** Scanner used for scanning microarrays after hybridization.

APPENDIX I. PCR PRODUCTS SPOTTED ON MICROARRAY

**Table 4.** Concentration of PCR products spotted on microarray.

<b>Clone ID</b>	<b>OD 260</b>	<b>OD 280</b>	<b>Ratio</b>	<b>[DNA] ng/ul</b>
T32341	0.554	0.303	1.830	27.700
TC68180	0.744	0.407	1.830	37.200
TC67891	0.719	0.398	1.810	35.900
TC1623	0.808	0.449	1.800	40.400
TC50148	0.787	0.413	1.900	39.300
T71919	0.531	0.293	1.810	26.500
TC70632	0.964	0.523	1.840	48.200
TC67686	0.902	0.489	1.840	45.100
T54693	0.799	0.434	1.840	40.000
T00375	0.785	0.430	1.830	39.300
TC67905	1.067	0.589	1.810	53.400
TC67906	1.061	0.567	1.870	53.100
TC67846	0.905	0.484	1.870	45.300
T61921	0.772	0.415	1.860	38.600
T64048	0.623	0.340	1.830	31.200
HRV3	1.588	0.861	1.850	79.400
HRV4	1.833	1.005	1.820	91.700
HRV11	1.776	0.980	1.810	88.800
HRV19	1.666	0.903	1.850	83.300
HRV24	1.818	1.001	1.820	90.900
HRV36	1.741	0.935	1.860	87.000
HRV42	1.607	0.867	1.850	80.300
HRV47	1.497	0.816	1.840	74.900
HRV48	1.821	0.986	1.850	91.100
HRV54	1.677	0.910	1.840	83.900
HRV56	1.483	0.805	1.840	74.200
HRV63	1.423	0.779	1.830	71.200
HRV71	1.566	0.852	1.840	78.300
HRV76	1.763	0.958	1.840	88.100
HRV83	2.117	1.141	1.850	105.800
HRV88	1.594	0.869	1.830	79.700
HRV92	1.676	0.917	1.830	83.800
pUC19	1.068	0.597	1.790	53.400
Blank	0.000	0.000	0.000	0.000

## APPENDIX J. MICROARRAY .GAL FILE

"Type=GenePix ArrayList V1.0"				
"Block"	"Row"	"Column"	"ID"	"Name"
1	1	1	T32341	VP4VP2-36
1	1	2	T32341	VP4VP2-36
1	1	3	T32341	VP4VP2-36
1	1	4	TC68180	VP4VP2-73
1	1	5	TC68180	VP4VP2-73
1	1	6	TC68180	VP4VP2-73
1	1	7	TC67891	VP4VP2-12
1	1	8	TC67891	VP4VP2-12
1	1	9	TC67891	VP4VP2-12
1	1	10	T21623	VP4VP2-32
1	1	11	T21623	VP4VP2-32
1	1	12	T21623	VP4VP2-32
1	2	1	TC50148	VP4VP2-51
1	2	2	TC50148	VP4VP2-51
1	2	3	TC50148	VP4VP2-51
1	2	4	T71919	VP4VP2-4
1	2	5	T71919	VP4VP2-4
1	2	6	T71919	VP4VP2-4
1	2	7	TC70632	VP4VP2-51
1	2	8	TC70632	VP4VP2-51
1	2	9	TC70632	VP4VP2-51
1	2	10	TC67686	VP4VP2-19
1	2	11	TC67686	VP4VP2-19
1	2	12	TC67686	VP4VP2-19
1	3	1	T54693	VP4VP2-13
1	3	2	T54693	VP4VP2-13
1	3	3	T54693	VP4VP2-13
1	3	4	T00375	VP4VP2-45
1	3	5	T00375	VP4VP2-45
1	3	6	T00375	VP4VP2-45
1	3	7	TC67905	VP4VP2-10
1	3	8	TC67905	VP4VP2-10
1	3	9	TC67905	VP4VP2-10
1	3	10	TC67906	VP4VP2-8
1	3	11	TC67906	VP4VP2-8
1	3	12	TC67906	VP4VP2-8
1	4	1	TC67846	VP4VP2-4
1	4	2	TC67846	VP4VP2-4
1	4	3	TC67846	VP4VP2-4
1	4	4	TC1921	VP4VP2-1A

1	4	5	TC1921	VP4VP2-1A
1	4	6	TC1921	VP4VP2-1A
1	4	7	T64048	VP4VP2-71
1	4	8	T64048	VP4VP2-71
1	4	9	T64048	VP4VP2-71
1	4	10	HRV3	5NCR-HRV3
1	4	11	HRV3	5NCR-HRV3
1	4	12	HRV3	5NCR-HRV3
1	5	1	HRV4	5NCR-HRV4
1	5	2	HRV4	5NCR-HRV4
1	5	3	HRV4	5NCR-HRV4
1	5	4	HRV11	5NCR-HRV11
1	5	5	HRV11	5NCR-HRV11
1	5	6	HRV11	5NCR-HRV11
1	5	7	HRV19	5NCR-HRV19
1	5	8	HRV19	5NCR-HRV19
1	5	9	HRV19	5NCR-HRV19
1	5	10	HRV24	5NCR-HRV24
1	5	11	HRV24	5NCR-HRV24
1	5	12	HRV24	5NCR-HRV24
1	6	1	HRV36	5NCR-HRV36
1	6	2	HRV36	5NCR-HRV36
1	6	3	HRV36	5NCR-HRV36
1	6	4	HRV42	5NCR-HRV42
1	6	5	HRV42	5NCR-HRV42
1	6	6	HRV42	5NCR-HRV42
1	6	7	HRV47	5NCR-HRV47
1	6	8	HRV47	5NCR-HRV47
1	6	9	HRV47	5NCR-HRV47
1	6	10	HRV48	5NCR-HRV48
1	6	11	HRV48	5NCR-HRV48
1	6	12	HRV48	5NCR-HRV48
1	7	1	HRV54	5NCR-HRV54
1	7	2	HRV54	5NCR-HRV54
1	7	3	HRV54	5NCR-HRV54
1	7	4	HRV56	5NCR-HRV56
1	7	5	HRV56	5NCR-HRV56
1	7	6	HRV56	5NCR-HRV56
1	7	7	HRV63	5NCR-HRV63
1	7	8	HRV63	5NCR-HRV63
1	7	9	HRV63	5NCR-HRV63
1	7	10	HRV71	5NCR-HRV71
1	7	11	HRV71	5NCR-HRV71
1	7	12	HRV71	5NCR-HRV71

1	8	1	HRV76	5NCR-HRV76
1	8	2	HRV76	5NCR-HRV76
1	8	3	HRV76	5NCR-HRV76
1	8	4	HRV83	5NCR-HRV83
1	8	5	HRV83	5NCR-HRV83
1	8	6	HRV83	5NCR-HRV83
1	8	7	HRV88	5NCR-HRV88
1	8	8	HRV88	5NCR-HRV88
1	8	9	HRV88	5NCR-HRV88
1	8	10	HRV92	5NCR-HRV92
1	8	11	HRV92	5NCR-HRV92
1	8	12	HRV92	5NCR-HRV92
1	9	1	pUC19	pUC19
1	9	2	pUC19	pUC19
1	9	3	pUC19	pUC19
1	9	4	Blank	Blank
1	9	5	Blank	Blank
1	9	6	Blank	Blank
1	9	7	Blank	Blank
1	9	8	Blank	Blank
1	9	9	Blank	Blank
1	9	10	Empty	Empty
1	9	11	Empty	Empty
1	9	12	Empty	Empty
2	1	1	T32341	VP4VP2-36
2	1	2	T32341	VP4VP2-36
2	1	3	T32341	VP4VP2-36
2	1	4	TC68180	VP4VP2-73
2	1	5	TC68180	VP4VP2-73
2	1	6	TC68180	VP4VP2-73
2	1	7	TC67891	VP4VP2-12
2	1	8	TC67891	VP4VP2-12
2	1	9	TC67891	VP4VP2-12
2	1	10	T21623	VP4VP2-32
2	1	11	T21623	VP4VP2-32
2	1	12	T21623	VP4VP2-32
2	2	1	TC50148	VP4VP2-51
2	2	2	TC50148	VP4VP2-51
2	2	3	TC50148	VP4VP2-51
2	2	4	T71919	VP4VP2-4
2	2	5	T71919	VP4VP2-4
2	2	6	T71919	VP4VP2-4
2	2	7	TC70632	VP4VP2-51
2	2	8	TC70632	VP4VP2-51

2	2	9	TC70632	VP4VP2-51
2	2	10	TC67686	VP4VP2-19
2	2	11	TC67686	VP4VP2-19
2	2	12	TC67686	VP4VP2-19
2	3	1	T54693	VP4VP2-13
2	3	2	T54693	VP4VP2-13
2	3	3	T54693	VP4VP2-13
2	3	4	T00375	VP4VP2-45
2	3	5	T00375	VP4VP2-45
2	3	6	T00375	VP4VP2-45
2	3	7	TC67905	VP4VP2-10
2	3	8	TC67905	VP4VP2-10
2	3	9	TC67905	VP4VP2-10
2	3	10	TC67906	VP4VP2-8
2	3	11	TC67906	VP4VP2-8
2	3	12	TC67906	VP4VP2-8
2	4	1	TC67846	VP4VP2-4
2	4	2	TC67846	VP4VP2-4
2	4	3	TC67846	VP4VP2-4
2	4	4	TC1921	VP4VP2-1A
2	4	5	TC1921	VP4VP2-1A
2	4	6	TC1921	VP4VP2-1A
2	4	7	T64048	VP4VP2-71
2	4	8	T64048	VP4VP2-71
2	4	9	T64048	VP4VP2-71
2	4	10	HRV3	5NCR-HRV3
2	4	11	HRV3	5NCR-HRV3
2	4	12	HRV3	5NCR-HRV3
2	5	1	HRV4	5NCR-HRV4
2	5	2	HRV4	5NCR-HRV4
2	5	3	HRV4	5NCR-HRV4
2	5	4	HRV11	5NCR-HRV11
2	5	5	HRV11	5NCR-HRV11
2	5	6	HRV11	5NCR-HRV11
2	5	7	HRV19	5NCR-HRV19
2	5	8	HRV19	5NCR-HRV19
2	5	9	HRV19	5NCR-HRV19
2	5	10	HRV24	5NCR-HRV24
2	5	11	HRV24	5NCR-HRV24
2	5	12	HRV24	5NCR-HRV24
2	6	1	HRV36	5NCR-HRV36
2	6	2	HRV36	5NCR-HRV36
2	6	3	HRV36	5NCR-HRV36
2	6	4	HRV42	5NCR-HRV42

2	6	5	HRV42	5NCR-HRV42
2	6	6	HRV42	5NCR-HRV42
2	6	7	HRV47	5NCR-HRV47
2	6	8	HRV47	5NCR-HRV47
2	6	9	HRV47	5NCR-HRV47
2	6	10	HRV48	5NCR-HRV48
2	6	11	HRV48	5NCR-HRV48
2	6	12	HRV48	5NCR-HRV48
2	7	1	HRV54	5NCR-HRV54
2	7	2	HRV54	5NCR-HRV54
2	7	3	HRV54	5NCR-HRV54
2	7	4	HRV56	5NCR-HRV56
2	7	5	HRV56	5NCR-HRV56
2	7	6	HRV56	5NCR-HRV56
2	7	7	HRV63	5NCR-HRV63
2	7	8	HRV63	5NCR-HRV63
2	7	9	HRV63	5NCR-HRV63
2	7	10	HRV71	5NCR-HRV71
2	7	11	HRV71	5NCR-HRV71
2	7	12	HRV71	5NCR-HRV71
2	8	1	HRV76	5NCR-HRV76
2	8	2	HRV76	5NCR-HRV76
2	8	3	HRV76	5NCR-HRV76
2	8	4	HRV83	5NCR-HRV83
2	8	5	HRV83	5NCR-HRV83
2	8	6	HRV83	5NCR-HRV83
2	8	7	HRV88	5NCR-HRV88
2	8	8	HRV88	5NCR-HRV88
2	8	9	HRV88	5NCR-HRV88
2	8	10	HRV92	5NCR-HRV92
2	8	11	HRV92	5NCR-HRV92
2	8	12	HRV92	5NCR-HRV92
2	9	1	pUC19	pUC19
2	9	2	pUC19	pUC19
2	9	3	pUC19	pUC19
2	9	4	Blank	Blank
2	9	5	Blank	Blank
2	9	6	Blank	Blank
2	9	7	Blank	Blank
2	9	8	Blank	Blank
2	9	9	Blank	Blank
2	9	10	Empty	Empty
2	9	11	Empty	Empty
2	9	12	Empty	Empty

## APPENDIX K. EXAMPLE OF MICROARRAY DATA ANALYSES




Figure 10. Example of alignment of .GAL file with the top subarray.




Figure 11. Example of microarray hybridization signals sorted based on highest signal strength.